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Osteoarthritis (OA) is one of the most common joint diseases 
worldwide with an estimated prevalence of 15%1,2. It is a 
degenerative joint disease, mainly targeting knee, hip, hand, feet 
and/or spine. OA is characterized by a gradual degeneration of 
the cartilage eventually leading to failure of the synovial joints3. 
Loss of cartilage matrix and joint space alterations, such as 
subchondral bone sclerosis and new bone formation by 
osteophytes are common clinical manifestations of the disease. 
Even though age is an important risk factor for the development 
of OA it cannot be considered as a simple degenerative process 
in elderly. The current paradigm looks at OA as a disease 
involving the whole joint4,5. The joint is an organ in which 
several tissues and cell types are in close proximity and show 
important functional interactions with each other: failure of one 
component will influence the others and can affect the function 
of the whole joint6. 
1.1. Main joint tissue components  
The knee and hip joints are the two largest weight bearing 
synovial joints of the human body (figure 1). The synovial 
membrane, a semi permeable soft tissue structure lining the 
joint spaces, encases the synovial fluid and provides nutrition 
to the chondrocytes in the cartilage. The healthy synovium is 
populated with a small number of macrophages and synovial 
fibroblasts which heavily proliferate during inflammation7–9. In 
this thesis cartilage and fibrocartilage have been the main focus.  
12 
 
         
 
Figure 1: basic anatomical structure of the human knee (left) and hip (right) joint  
Hyaline cartilage covers the articular joint surfaces and protects 
against biomechanical impact by distributing loading evenly 
and reducing friction by lubrication10. Both knee and hip joints 
have a fibrocartilagenous structure incorporated in the joint 
capsule: the menisci in the knee and the acetabular labrum in 
the hip. These are similar in shape and structure. Even though 
they have different functions, they both aim to protect the 
articular cartilage from degradation. Loss of function of these 
structures, for example after meniscus resection, increases the 
risk for OA development severely as reviewed by Englund and 
collegues11. Animal OA models such as destabilization of the 
medial meniscus (DMM) and anterior crucial ligament 
transection (ACLT) are based hereon and widely used in OA 
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research. The menisci are specialized shock absorbers, they 
facilitate load transmission in the joint by providing a larger 
contact area between the round femoral condyles and the flat 
tibial plateau. The acetabular labrum is mainly a sealing 
structure that seals/covers the femoral head in the acetabulum 
and protects against fluid flow in or out the joint space. This 
maintains the fluid pressure in the joint, ensuring more uniform 
distribution of forces on the cartilage. In this way, the 
acetabular labrum might also protect the articular cartilage 
from degradation1. 
Cartilage 
The articular cartilage is a hyaline cartilage. It is an avascular, 
alymphatic, aneural connective tissue composed of an 
extracellular matrix (ECM) populated by a sparse number of 
chondrocytes. Chondrocytes are the only resident cells in 
articular cartilage and although they only make up 2% of the 
total cartilage volume they are responsible for ECM synthesis 
and turnover10,13,14. Each chondrocyte is surrounded by ECM 
(figure 2), the region adjacent to the chondrocytes is called the 
pericellular matrix (PCM). Together they are sometimes referred 
to as the chondron. 
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Figure 2: Schematic view of a chondrocyte and the surrounding ECM15. 
Chondrocytes are embedded in an extracellular matrix. The matrix can be subdivided 
according to the proximity to the chondrocyte. HA: hyaluronic acid; PG: proteoglycan; 
R: receptors 
 
The PCM consists primarily of proteoglycans and is thought to 
play a critical role in transducing biomechanical and 
biochemical signals16–18. Fine collagen fibrils provide a 
basketlike structure around the cells in the territorial region. 
The interterritorial region is the largest region and consist of 
large collagen fibril bundles which contribute to biomechanical 
cartilage properties and are arranged in specific patterns 
depending on which layer they are situated in10,14,19. Articular 
cartilage can be divided in four different layers with distinct 
matrix structure and chondrocyte phenotype: 
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superficial/tangential zone, middle/transitional zone, deep 
zone and the calcified layer (figure 3).  
 
Figure 3: zonal compartmentalization of articular cartilage. Chondrocytes 
transition from randomly distributed and flat (superficial zone) to round shaped and 
column distributed (deep zone). Collagen fibrils change from parallel to surface 
(superficial zone) towards perpendicular to it (deep zone) and increase in thickness. 
The superficial zone consists of collagen fibrils parallel 
orientated to the articular surface, abundantly populated with 
flat chondrocytes. In the transitional zone the orientation of 
collagen fibrils and chondrocytes, which are spheric here, 
changes to a more random distribution. It is the deep zone that 
provides most resistance to compressive forces. The collagen 
fibrils have a large diameter and are orientated perpendicular to 
the articular surface. Chondrocytes in this layer are typically 
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large, round shaped and arranged in columns parallel to the 
collagen fibrils. In the calcified zone the collagen fibrils are 
anchored into the subchondral bone, firmly attaching the 
cartilage to the bone. The layer is populated with a small 
number of hypertrophic chondrocytes10,13,19. 
The extracellular matrix is composed mainly of a large amount 
of water, collagens (mainly collagen type II), proteoglycans and 
a small number of other components (lipids, glycoproteins, non-
collagenous proteins, SLRPs). Collagen type II forms triple helix 
structures stabilized by several other collagen types (type I, IV, 
V, VI, IX and XI). It is this triple helix matrix that largely 
contributes to the shear and tensile stress resistance of the 
articular cartilage10,20–22. Proteoglycans are divided in large and 
small proteoglycans based on the size of their protein core. On 
the protein core one or several glycosaminoglycan (GAG) chains 
are attached. Aggrecan, a large proteoglycan, is the most 
abundant proteoglycan in articular cartilage. It consists of many 
GAG chains, mostly chondroitin sulfate and keratin sulphate. 
Aggrecan binds in large aggregates to hyaluronan. Furthermore, 
due to extensive negative charge, aggrecan is highly hydrophilic 
which attracts and retains water to the interfibrillar zones23,24. 
The small proteoglycans are also known as small leucine rich 
repeat proteoglycans (SLRPs), because of several leucine rich 
repeats in their core protein25,26. They are further divided in five 
classes base upon biological activity, structure and 
chromosomal organization: Class I (biglycan, decorin, asporin, 
ECM-2), class II (fibromodulin, lumican, keratocan, 
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osteomodulin, PRELP), class III (osteoglycin, opticin, 
epiphycan), class IV (chondroadherin, nyctolopin, tukushi) and 
class V (podocan, podocan-like protein 1)25–27.  
 
Figure 4: schematic overview of SLRP family members structure (adapted from 
glycoworld; www.glycoforum.gr.jp) 
SLRPs are structural components of the ECM with binding sites 
for collagen, hereby protecting the collagen fibrils from 
degradation by proteases26,28. However, increasing evidence 
indicates SLRPs are also involved in several signaling pathways 
as will be discussed later in this introduction29–32. 
Menisci and acetabular labrum 
Both meniscus and acetabular labrum have a triangular 
crosssection33. Histologically, the meniscus is divided in three 
zones: the superficial zone (in contact with the synovium), outer 
fibrous zone (resistant to tensile forces) and the inner zone 
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which resists mainly compressive forces34,35. The acetabular 
labrum is divided into a dense connective tissue, the capsular 
side and the fibrocartilagenous articular side36. Both labrum 
and meniscus are populated with a relative abundant number 
of spindle shaped fibrochondrocytes in contrast with the sparse, 
mostly round shaped, chondrocytes which populate the 
articular cartilage37. These fibrochondrocytes are similar in 
menisci and acetabular labrum but distinct to chondrocytes not 
only in morphology but also in their protein expression pattern. 
Whereas the cartilage ECM contains large collagen type II fibrils, 
these fibrochondrocytes release more collagen type I in the 
ECM, giving rise to fibrocartilage rather than cartilage. Similar 
to chondrocytes, fibrochondrocytes will induce production of 
several matrix degrading proteins in response to pro-
inflammatory stimuli and thus contribute to the homeostasis of 
the ECM in which they are embedded37. Whereas the 
metabolism of chondrocytes in articular cartilage is very well 
studied, much less is known about the cellular homeostasis in 
fibrocartilagenous tissues such as meniscus and labrum. 
1.2. Inside osteoarthritis 
Disturbed cartilage homeostasis and low level 
inflammation 
In the early years of OA research, OA was believed to be merely 
a disease of mechanical cartilage erosion. Later on, it became 
clear that an altered chondrocyte metabolism is crucial in the 
development of osteoarthritis. In consequence, the chondrocyte 
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metabolism was extensively studied during the last two 
decades. Nowadays, it has become clear that OA is a disease of 
the whole joint involving interactions between the synovium, 
components of the immune system, bone and cartilage. 
In healthy adult cartilage a low turnover of ECM is maintained 
by resting chondrocytes with a half-life of a few decennia for 
aggrecan38 and over 100 years for collagen39. In OA the 
chondrocytes become activated, start to proliferate and shift to 
a hypertrophic phenotype. Their expression and secretion 
profile changes towards a catabolic environment3,40. Although 
long believed to be a non-inflammatory arthritis, the current 
scientific opinion is that at least a low level of inflammation can 
be observed in OA patients41,42. However, there still exists 
controversy whether this inflammation is primary or secondary 
to cartilage damage43. Most of the current evidence suggests 
that initial mechanical damage or wear and tear triggers 
inflammatory responses in the joint tissue, which increases 
catabolic activity and further induces ECM degradation. These 
degradation products can upregulate inflammatory pathways 
and genes, generating a feedback loop which drives OA 
progression44. Indeed, a low grade activation of the synovial 
membrane has been observed in OA patients, enforcing this 
hypothesis45–47.  
Chondrocyte mediated cartilage degradation 
In OA the balance between matrix synthesis and degradation is 
disrupted. Chondrocytes, the only resident cell type in articular 
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cartilage play an important role in this dysregulation. During 
the course of OA chondrocytes undergo a process of activation 
and transdifferentiation48. They develop a phenotype 
characterized by a prominent Golgi apparatus and ER49, to 
increase their secretory potential. Initially these 
transdifferentiated chondrocytes increase production of matrix 
components (e.g. collagen 2) in an attempt to restore the 
extracellular matrix. Gradually the chondrocytes protein 
secretion shifts away from repair, towards a degrading pattern, 
characterized by large amounts of proteoglycan degrading 
enzymes (e.g. aggrecanase) and collagen degrading matrix 
metalloproteinases MMP’s (e.g. MMP13) are produced48. This 
massive production and secretion of proteins induces severe 
cellular stress to the chondrocytes50. A fraction of them will 
undergo apoptosis and die (also known as chondroptosis)51–53. 
Since proteoglycans protect the collagen fibril from degradation, 
initial protection from proteoglycan depletion protects against 
OA progression since no collagen degradation can occur54. 
Destruction of aggrecan, the major proteoglycan of the cartilage 
ECM, is mediated by two aggrecanases of the A disintegrin and 
metalloproteinase domain with thrombospondin motifs 
(ADAMTS) family, ADAMTS-4 and ADAMTS-554,55. Both 
aggrecanases seem to be essential in aggrecan degradation 
however monoclonal antibodies against ADAMTS-5 have 
recently been shown to be more effective against OA cartilage 
damage56,57. In a later stage of OA progression matrix 
degradation is focused on collagen cleavage58. In humans this 
is mostly mediated by MMP’s, most potently by MMP-1355,58,59. 
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Figure 5: Overview of chondrocyte differentiation, involved growth factors and 
produced ECM proteins60  
The proteolytic enzymes described above are the main effectors 
of cartilage degradation in OA. Several cytokines and growth 
factors are known to drive the secretion of these effector 
enzymes. IL-1β and TNFα are the most catabolic signaling 
molecules in OA61, stimulating the production of cartilage 
degrading enzymes by chondrocytes through MAPK and NFκB 
signaling pathways3,62,63. IL-1β and TNFα are endogenously 
produced by chondrocytes but also by synovial fibroblasts. In 
addition to increased matrix catabolism, IL-1β and TNFα inhibit 
anabolic matrix synthesis through downregulation of collagen 
type II and aggrecan64,65. Growth factors also play an important 
role in regulating chondrocyte metabolism. Overactivation of 
pathways involved in endochondral bone development is 
strongly associated with OA progression. For example, Wnt/β-
catenin signaling is critical for chondrocyte homeostasis. 
Overactivation leads to chondrocyte dedifferentiation and 
increased MMP-13 expression66,67. Activation of Indian 
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hedgehog protein (Ihh) induces ADAMTS-5 and MMP-1368. TGF-
β family signaling is essential in cartilage development but also 
contributes to OA pathology69,70. BMP signaling is considered 
mostly anabolic in chondrocyte metabolism, moreover BMP-2 
has been shown to be involved in OA osteophyte formation71–74. 
Reports on TGF-β are even more complex and 
controversial70,75,76. Distinct effects are exerted on 
chondrocytes, synovial fibroblasts and bone, furthermore even 
within one cell type different microenvironments may implicate 
different TGF-β effects77. For example TGF-β is critical in 
osteophyte formation78,79 and it stimulates synovial fibroblasts 
to produce IL-1β and TNFα80. On the other hand, TGF-β inhibits 
hypertrophic chondrocyte differentiation81 and mutations and 
SNP’s associated with inhibition of TGF-β signaling are related 
to an increased susceptibility to OA82,83. This demonstrates the 
duality of TGF-β signaling in OA. It is now hypothesized that 
canonical TGF-β signaling through SMAD2/3 pathway exerts 
TGF-β induced anabolic events whereas non canonical 
SMAD1/5/8 signaling is responsible for TGF-β-induced 
catabolism76,84–86. Finally, ECM components itself can also exert 
catabolic effects, for instance fibronectin and collagen 
fragments activate ERK, JNK and p38 signaling through binding 
to the integrin receptor, thereby further inducing MMP13 
expression87,88. 
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Figure 6: Overview of processes in joint degradation during OA (adapted from 
Glyn-Jones et al.89). The osteoarthritic  joint is characterized by several features such 
as cartilage erosions, osteophyte formation and chondrocyte hypertrophy. 
Role for subtle inflammation on chondrocyte 
homeostasis and ECM destruction  
Until the beginning of this century, the view on osteoarthritis 
could be summarized by the previous paragraph. OA was 
considered as a primarily chondrocyte driven imbalance of 
homeostasis. OA is not a prototype inflammatory arthritis, like 
rheumatoid arthritis or spondyloarthropathies. There is no 
autoimmune or autoinflammatory component in the disease 
etiology. However, in the past years the field has gradually 
accepted a role for a subtle inflammation in driving this 
imbalance as well as the involvement of the whole joint in the 
OA pathogenesis. For instance, synovitis has been observed in 
at least a significant subset of OA patients both early and late 
disease staged42,90. Moreover mononuclear cell infiltration is 
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observed to be more abundant in early OA compared to late 
OA91. Additionally, toll like receptor 2 (TLR2) and TLR4 
expression in OA chondrocytes are increased92,93. These 
receptors respond not only to peptidoglycan or LPS but also to 
endogenous danger signals (DAMP’s) released from stressed and 
dying cells. In OA these receptors have been shown to bind 
S100A4, S100A8, S100A9, low molecular weight hyaluronic 
acid (LMW-HA) and high mobility group box chromosome 
protein 1 (HMGB1 ) all of which are elevated in OA tissue. In 
addition it has recently been suggested that ECM components 
can act as DAMP’s after being cleaved from the ECM. These 
DAMP’s bind toll like receptors which promote cartilage 
degradation via MyD88 and subsequent NFκB signaling94–96. 
Moreover, complement activation has recently been proven to 
be crucial in OA development. Complement activation and 
subsequent membrane attack complex (MAC) deposition has 
been observed in early stage OA joint tissue and is persistent 
throughout later OA disease stages. This activation of the 
complement cascade might be attributed to ECM components 
(e.g. fibromodulin, aggrecan, COMP) released after initial joint 
injury97–99. Deposition of MAC around OA chondrocytes will 
either be lytic and cause chondrocyte cell death or induce 
expression of matrix degrading enzymes and pro-inflammatory 
mediators. Interestingly, MAC deposition in the absence of cell 
death will also induce the expression of complement effectors in 
chondrocytes. This might be synergetic with the complement 
activation in OA synovial tissue and amplify complement 
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signaling. Treatment of mice with anti-C5 antibodies or fusion 
protein inhibiting C5 activation reduces OA development in 
murine OA models97. This suggests complement cascade 
activation is crucial to OA pathology.  
 
Figure 7: Role of complement activation in OA. ECM fragments released after initial 
damage activate the complement cascade, increasing membrane attack complex (MAC) 
deposition. This will lead to cell dead or release of catabolic mediators in chondrocytes 
(adapted from Haas et al.100) 
In conclusion, the current paradigm suggests low level 
inflammation, induced upon initial cartilage damage, is 
essential in the progression from initial injury towards full OA 
development. 
1.3. Role of SLRP in degenerative joint 
diseases 
As mentioned above apart for collagen and large proteoglycans, 
the small proteoglycans and SLRP’s are important structural 
components of the ECM as well. The family consists of 18 
members divided in 5 classes based on shared activity22–24,27,29. 
Their specific structure, consisting of a small protein core with 
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LRR’s and variable glycosaminoglycan side chains makes them 
extremely well suited for protein-protein interactions. They are 
able to bind several cell surface receptors, growth factors and 
cytokines29,101. Several SLRP knock out mice models have been 
shown to exhibit an OA-like phenotype102–109. The exact 
mechanism behind the suggested involvement of SLRP’s in OA 
development still remains elusive but there might be a 
contribution of their ability to influence several signaling 
pathways. Concerning the role for SLRP’s in degenerative joint 
diseases, different aspects of the SLRP should be considered. 
On the one hand they are important for ECM homeostasis, they 
function as a coating surrounding the collagen network, 
protecting it from cleavage by MMP’s101. Moreover asporin 
influences collagen mineralization which might contribute to OA 
pathology110. On the other hand, protein-protein interactions 
may be, at least, equally as important in understanding how 
these SLRP could be involved in osteoarthritis. 
SLRP-TGFβ superfamily interactions  
TGF-β family members are very important in chondrocyte 
biology and cartilage maintenance. Several SLRP’s are known 
to signal via the superfamily110 or be regulated by the TGF-β 
superfamily110,111. Different branches of the TGF-β superfamily 
may influence SLRP expression differently. Osteoadherin, also 
known as osteomodulin (OMD) expression is induced by BMP-
2 whereas TGF-β1 mediates OMD downregulation. The BMP-4 
signaling can be inactivated through binding with biglycan. 
With regard to TGF-β, more complex interactions have been 
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described. Decorin, biglycan, asporin and fibromodulin are 
known to bind TGF-β31,32 with activating or inhibitory effects 
depending on the cell specific context. In cartilage, most 
evidence points to an inhibition of TGF-β signaling by decorin, 
whereas biglycan and fibromodulin induces an overactivation 
of TGF-β signaling pathways. 
The case of asporin and TGF-β is particularly interesting and 
may therefore serve as a perfect example to demonstrate the 
complexity of interactions between SLRP’s and the TGF-β 
family (as recently reviewed by Lei and collegues110). There has 
been increasing evidence for asporin involvement in OA. 
Association studies, trying to link polymorphisms in the 
asporin gene with OA susceptibility, have generated 
inconsistent results. Asporin’s pro-osteoarthritic effects 
mediated via TGF-β are well documented110. Asporin’s binding 
to TGF-β1 inhibits binding with TGF-β RI/RII receptor 
complex. In this way, it is able to inhibit canonical SMAD 2/3 
pathway downstream of this receptor, thus inhibiting 
chondrogenesis and other anabolic TGF-β effects. It seems 
asporin-TGF-β interaction does not inhibit the SMAD 1/5/8 
pathway, which is responsible for catabolic events occurring in 
OA attributed to TGF-β such as MMP-13 induction, 
subsequent cartilage erosion and osteophyte formation. This 
suggests asporin might be involved in the shift from mainly 
anabolic SMAD 2/3 TGF-β signaling towards more catabolic 
SMAD 1/5/8 signaling observed in OA. Interestingly, TGF-β 
itself regulates asporin expression through the canonical 
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pathway. This implies a regulatory feedback loop exists 
between asporin and TGF-β110. 
 
Figure 8: Schematic overview of Asporin and TGFβ interactions. Asporin-bond TGF-
β1 is inhibited form binding the ALK-5/TGF-β RII complex which signals through SMAD 
2/3 and activates transcription of mainly anabolic cartilage genes. Whereas binding to 
the ALK-1/TGF-β RII complex, signalling through the catabolic SMAD 1/5/8 pathway 
is not inhibited by Asporin binding. 
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Immunomodulatory role of SLRP’s  
In recent years increasing evidence has indicated a role for 
soluble SLRP’s in regulation of immune responses, mainly in 
innate immunity. Several SLRP’s interact with complement 
system components, either to activate (e.g. fibromodulin and 
lumican) or inhibit (e.g. biglycan and decorin) classical 
complement activation through binding with C1qM101,111. 
Another way the SLRP’s can regulate inflammatory responses is 
by activating pattern recognition receptors (PRR). Both TLR’s 
and NLR’s possess LRR-motifs which allow them to interact with 
other LRR-containing proteins, such as SLRP’s112,113. Lumican 
can activate TLR4114 and biglycan has been extensively reported 
to activate both TLR2 and 4. Through this interaction, biglycan 
induces TNFα and MIP-2 synthesis115. Biglycan interaction 
induces a clustering of TLR2/4 and purinergic P2X receptors in 
macrophages which increases pro-IL-1β synthesis and in 
addition directly activates the NLRP3 inflammasome which 
induces an increased release of mature IL-1β116. Interestingly, 
only soluble SLRP’s are able to induce these immune responses. 
Recent evidence suggests soluble forms of SLRP’s are released 
during tissue injury or stress by proteolysis from to ECM. 
However, activated macrophages have been shown to secrete 
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soluble biglycan. This might potentiate immune signaling via 
biglycan as a DAMP115.  
 
Figure 9: Schematic view of SLRP’s interactions with the innate immune 
system111. Decorin and biglycan induce inflammation through activation of TLR2/4 
pathways. Activation of the inflammasome through purinergic receptors by biglycan 
increases IL-1β levels. IL-10 levels are reduced by decorin-TGFβ binding through 
elevated PDCD4 via miR-21 reduction. 
Decorin also functions as a danger signal through TLR2/4 
binding and induces PDCD4 expression, an IL-10 inhibitor, 
thereby dampening anti-inflammatory response117. However 
decorin can induce a hyper-inflammatory state since it is able 
to stop normal PDCD4 inhibition, inducing a decline in mi-R21, 
a PDCD4 inhibitor, through binding and blocking of TGF-β. In 
this way IL-10 will be inhibited continuously and inflammation 
cannot be resolved117,118. Although most interactions of SLRP’s 
seem to be with the innate immune system, SLRP’s appear to 
have an influence on adaptive immunity as well. For instance 
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biglycan, induces CXCL13 expression in macrophages and 
dendritic cells which mediates B cell recruitment119. Moreover 
biglycan is a ligand for CD44 and is suggested in CD16- NK cell 
recruitment120. 
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1.4. Role of heat shock proteins in stromal 
tissue of the joints 
 
Adapted from:  
Heat-shock proteins in stromal joint tissues: innocent 
bystanders or disease-initiating proteins? 
Stijn Lambrecht, Nele Juchtmans and Dirk Elewaut 
 
 
 
 
 
 
 
 
 
 
 
Rheumatology (2014) 53 (2): 223-232. 
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The name heat-shock proteins (HSPs) originates from their 
initial identification as stress-inducible proteins that act as an 
intracellular defense mechanism against thermal stress. 
Functionally, stress-inducible proteins can be classified into 
seven classes, including chaperones, cytoskeletal proteins and 
metabolic enzymes (for an overview, see Richter et al121). The 
predominant class, in terms of expression level, across species 
is the initially discovered HSPs122. In this review we will 
specifically focus on this class. The primary characterization of 
HSPs suggested that they were largely regulated at the 
transcriptional level, however, subsequent mechanistic data 
have shown that HSPs have multiple levels of regulation, such 
as phosphorylation, oligomerization and protein interactions123. 
At the transcriptional level, the primary stress-inducible 
transcription factor is heat shock factor 1 (HSF1). Many HSPs 
also contain alternative promoter recognition sites, allowing for 
transcriptional activation via multiple signaling pathways123. 
The HSPs show a remarkable sequence homology between 
species, emphasizing their important biological role throughout 
evolution. In humans, the HSPs can be further subdivided into 
five classes: chaperonins (HSP10/HSP60, primarily located in 
the mitochondria), the HSP70 (HSPA/HSPH) family, the HSP40 
(dnaJ) family, the HSP90 (HSPC) family and the small HSPs 
(HSPb)124. HSPs have a long history in the arthritis research 
field. Ever since the discovery that T cells recognizing HSPs may 
elicit an arthritic phenotype, a lot of research has been 
conducted to study the role of HSPs in arthritis and how these 
can be used as diagnostic and/or therapeutic tools. This initial 
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discovery described the role of T cells recognizing HSP65 in 
eliciting arthritis125. It has been shown that T cells and 
antibodies isolated from arthritic animals and arthritis patients 
recognize different HSPs126. Surprisingly, despite the fact that 
HSPs are a major immune target, administration of purified 
bacterial HSPs does not induce arthritis127. It is now clear that 
endogenous HSPs are not immunogenic per se, but that the 
immunodominance of bacterial HSPs may induce cross-
reactivity with endogenous HSPs. Moreover, HSPs may 
associate with danger-associated molecular patterns (DAMPs) 
and pathogen-associated molecular patterns (PAMPs) or other 
antigenic peptides and thus alter the immune response to 
DAMPs and PAMPs, further emphasizing their immunological 
significance128. Recently it has become clear that immune 
responses to HSPs are very complex and may be arthritogenic 
as well as protective. This complex behavior may be explained 
by the presence of different epitopes, the method of immune 
activation and the administration route. How HSPs interact with 
the immune system in autoimmune diseases and arthritis has 
been extensively reviewed elsewhere129,130. In this review we will 
mainly focus on altered expression of HSPs by stromal joint 
compartments and how these can affect tissue biology and/or 
immune activation. An intriguing feature of HSPs is that they 
are located intracellularly, at the cell surface or even in the 
extracellular environment. Given the intimate contact between 
immune and stromal cells in the joint, the presentation of HSPs 
in the extracellular space by stromal cells may thus modulate 
the immune system and contribute to joint inflammation (Fig. 
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1). In contrast to the research focused on regulation of the 
immune system by HSPs in arthritis, studies on the direct 
biological function of HSPs in cells from the joint are rather 
limited, but they provide exciting avenues for future research.  
 
Figure 10: HSPs link stromal and immune cells in joint inflammation. HSPs are 
predominantly located in the intracellular environment where they primarily act as 
molecular chaperones. Cellular stress factors (including cytokines, Reactive Oxygen 
Species, heat, hypoxia) will trigger expression of HSPs, secretion of HSPs to the 
extracellular environment and/or translocation of HSPs to the cell membrane. In the 
extracellular environment, the HSPs can elicit an inflammatory as well as a toleration 
response, involving the innate and the adaptive immune system 
HSPs are predominantly located in the intracellular 
environment where they primarily act as molecular chaperones. 
Cellular stress factors (including cytokines, reactive oxygen 
species, heat, hypoxia) will trigger expression of HSPs, secretion 
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of HSPs to the extracellular environment and/or translocation 
of HSPs to the cell membrane. In the extracellular environment, 
the HSPs can elicit an inflammatory as well as a toleration 
response, involving the innate and the adaptive immune system 
HSPs: a collection of multiple protein families 
with pleiotropic effects in joint diseases 
HSP90 family  
The HSP90 protein family consists of 17 gene members divided 
into four classes based on phylogenetic analysis131. The HSP90 
family contains five members in humans124. This family has 
been implicated in the physiology of joint tissues in the past, 
even with therapeutic potential. Interestingly, HSP90 
expression varies with age. Moreover, the ability of a cell to 
respond to cellular stress by up-regulating HSP90 (among other 
HSPs) expression decreases with age132. Such a regulatory 
mechanism may be extremely relevant in degenerative diseases 
such as OA. Moreover, it is well known that HSP90 protects cells 
from apoptosis and interacts with a variety of substrates133, 
including signaling proteins such Akt134 and enzymes such as 
iNOS135. In RA fibroblast-like synoviocytes (FLS) it was shown 
that HSP90 protects synovial cells from apoptosis and thus 
contributes to synovial overgrowth via interaction with Akt and 
Erk136. Boehm et al.137 proposed a role for HSP90 in chondrocyte 
biology by demonstrating that HSP90 expression regulates 
MMP13 expression. However, specific blockade of HSP90β 
(HSPC3) by small interfering RNA (siRNA) induces MMP13 
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expression. This is probably due to destabilization of a protein 
complex that interacts with a specific MMP13 promoter site, 
thereby inhibiting MMP13 expression138. As MMP13 is one of 
the major proteases involved in cartilage breakdown, targeting 
these proteins was proposed as a potential cartilage repair 
strategy. Commonly used chemical blocking strategies, such as 
geldanamycin, do not necessarily have a strong specificity to one 
of the HSP90 proteins. Thus it is clear that more specific 
inhibitors await future development139. Kimura et al.140 
described a selective HSP90 inhibitor that specifically targets 
HSPC1 and more specifically induces HSF1 activation, thereby 
inducing HSP70 expression in cartilage, a protein known to 
prevent nitric oxide (NO)-induced apoptosis141, ultimately 
leading to reduced MMP13 levels. All of this work clearly 
suggests an important role for HSP90 proteins in chondrocyte 
biology. However, the in vivo impact of HSP90 blocking on 
cartilage metabolism in OA is still unclear. Such in vivo proof of 
principle was demonstrated in inflammatory arthritis models 
(CIA and AIA) by a small molecule inhibitor of HSP90142. The 
authors demonstrate reduced nuclear factor κB (NF-κB) nuclear 
translocation in synovial fibroblasts and reduced cytokine 
production upon compound administration. 
In conclusion, it is clear that HSP90 directly interferes with 
important pathological processes in chondrocytes and synovial 
fibroblasts such as NO synthesis, stabilization of signaling 
molecules (directly or by mediating other HSP expression) and 
angiogenesis. However, given the ubiquitous expression of 
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HSP90 and its pleiotropic interaction profile, it remains very 
questionable whether the HSP90 targeting strategies will have a 
sufficient therapeutic index, especially given observations that 
targeting of HSP90 may induce osteoclastogenesis in vitro143,144, 
which could worsen bone destruction in joint diseases. Thus it 
is likely that targeting HSP90 in one tissue may have beneficial 
effects, whereas in others detrimental effects may be observed. 
Overall, the therapeutic potential of HSP90 is therefore 
uncertain. Indeed, recent clinical studies in multiple myeloma 
with HSP90 inhibitors report adverse events such as 
thrombocytopenia, neutropenia and anemia145. 
HSP90 proteins may also play an important role in the 
interaction between stromal cells and the immune system. 
Overexpression and surface presentation of gp96 by stromal 
tissues under stress conditions such as inflammation may 
contribute to the chronicity of inflammation in arthritis. Gp96 
(or grp94) was shown to be elevated in RA synovial tissue. 
Moreover, the authors reported gp96 as a TLR2 ligand that 
activates macrophages and identified the protein as a potential 
contributor to chronic inflammation in RA146,147. It was shown 
in vivo that cell surface expression of gp96 elicits a 
proinflammatory lupus-like phenotype characterized by chronic 
stimulation of dendritic cells (DCs), which may represent an 
alternative pathway to initiate spontaneous autoimmune 
disease148. Additionally, fibroblasts overexpressing gp96 elicit a 
T cell activation involving antigen-presenting cells (APCs)149. 
Such interactions may be of major importance in arthritis 
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pathogenesis given the close proximity of stromal and immune 
cells in the joint. 
HSP70 family 
The HSP70 family is one of the most highly conserved chaperone 
families. Typically HSP70s never function alone. They require a 
co-factor such as J protein (HSP40 family) as well as nucleotide 
exchange factors. These co-factors act together as an HSP70 
machine to bind client proteins and nucleotides in an adenosine 
triphosphate (ATP)-dependent manner150. HSP70 has been 
mainly investigated in the inflammatory arthritis context, based 
on initial observations that bacterial HSP65 protected rats from 
adjuvant arthritis125. As stated above, in this review we do not 
focus on how HSPs may modulate the immune system and 
induce tolerance (see the review by Borges et al.151). HSP70 has 
primarily been investigated in synovial tissue. One of the 
landmark articles in this field described the enhanced 
expression of HSP70 in RA synovial tissue compared with OA 
tissue. In addition, the authors described the induction of 
HSP70 upon IL-1β and TNF-α stimulation but also under shear 
stress in synovial fibroblast-like cells152. This was later 
confirmed by Kang et al.153, who additionally showed that down-
regulation of HSP70 may protect synoviocytes from apoptosis. 
Furthermore, it was reported that HSP70 synovial fluid levels 
are elevated in RA patients. Indeed, whereas HSPs are generally 
accepted to act as an intracellular chaperone, the authors 
showed the release of HSP70 under stress conditions from 
viable cells154. Of great interest, in RA patients surface HSP70 
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expression was observed in a high percentage of synovial fluid 
cells, in particular DCs. Based on the known interactions 
between HSP70 and MHC class II shared epitopes, this may 
reflect an initiating mechanism in the activation of autoreactive 
T cells155. In contrast to the conventional role of HSPs as 
intracellular chaperones, Asea et al.156 and others have also 
described a cytokine role for HSP70. However, these reports 
have been rather controversial. Later on, subsequent 
studies157,158 have shown that lipopolysaccharide (LPS) 
contamination of HSP preparations may be responsible for these 
results. Thus caution is needed when interpreting results of 
data based on recombinant HSP preparations without stringent 
endotoxin control. Detanico et al.159 showed reduced TNF-α 
production by monocytes isolated from synovial fluid upon 
HSP70 stimulation. Interestingly, Luo et al.160 confirmed a 
similar role for extracellular HSP70 in suppressing cytokine 
release from tissue-derived FLS cultures upon TNF-α 
stimulation by inhibiting p38, extracellular regulated kinase 
(ERK) and Jun-N-terminal kinase (JNK) phosphorylation and 
clearly confirmed that LPS was not involved. These data 
provided evidence that extracellular HSPs have a direct effect on 
fibroblast-like synoviocytes. However, the in vivo relevance of 
these findings still needs to be demonstrated. 
The HSP70 family contains several more members, including 
HSP72. Administration of HSP72 in mice at the onset of arthritis 
reduced synovial inflammation by reduced NF-κB activation in 
the synovial tissue161. A particular member of the HSP70 family 
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is GRP78. The protein is expressed at the cell surface and can 
be detected in serum and synovial fluid162. Interestingly, the 
expression of GRP78 is elevated in the synovial lining and 
sublining of RA patients163. A direct pathogenic role on the 
synovium GRP78 (BiP, HSPA5) was recently demonstrated164. 
The authors confirmed that GRP78 levels are elevated in RA 
synovium and that in vitro down-regulation of GRP78 abolished 
TNF-induced synoviocyte proliferation and inhibited 
angiogenesis. In vivo data confirmed that GRP78 
haploinsufficient mice compared with wild-type control mice 
exhibit reduced arthritic symptoms, including synovial 
proliferation and angiogenesis. Induction of GRP78 alone, 
however, is not sufficient to induce arthritis and thus GRP78 
has been suggested to act as an important amplifying factor in 
synovial hyperplasia and arthritis164. Whereas GRP78 has a 
pathogenic role in the synovium, it has previously been shown 
that exogenous extracellular GRP78 helps to restore immune 
system homeostasis and thus resolve acute inflammation, 
mainly by acting on the myeloid lineage130. Overexpression of 
GRP78 was shown to prolong lifespan and increase the repair 
capacity of chondrocytes165, and it might play a crucial role in 
mineralization events during bone formation166, thus further 
demonstrating the pleiotropic effects of HSPs on different 
tissues. At least in cancer, the subcellular location of GRP78 
seems to determine the pro- or anti-tumor activity. Based on the 
parallels in the tumor environment and the synovial pannus, 
one can hypothesize that similar phenomena may occur in the 
42 
 
joint and may thus explain the contradictory role of GRP78 in 
arthritis130. 
In conclusion, along with the well-documented role of HSP70 
proteins in dampening inflammation by its direct tolerogenic 
effect on immune cells (primarily DCs and monocytes), HSP70 
proteins also have a direct effect on cell metabolism of articular 
cell types such as FLS and chondrocytes. 
HSP40 family 
The dnaJ, or HSP40 family, is functionally related to the HSP70 
family since the dnaJ proteins are necessary for HSP70 
chaperone function. The dnaJ proteins have an HSP70 binding 
domain and activate the ATPase activity required for chaperone 
function. It is probably the largest HSP family in humans, 
although very little is known in arthritis and joint diseases. The 
dnaJ family was first introduced by the discovery that RA 
patients show strong immune responses to bacterial dnaJ while 
normal subjects do not167. Based on the sequence homology 
between peptide sequences encoded by HLA genes and dnaJ 
genes, it has been proposed that in arthritis an interplay 
between HLA and dnaJ-derived peptides maintains and 
stimulates T cells, which participate in autoimmune 
inflammation168. Nowadays it is known that differential 
recognition of epitopes from human and bacterial dnaJ proteins 
may be a natural mechanism for amplifying and subsequently 
down-regulating inflammation169. Further research has 
indicated that tolerization with peptides derived from the dnaJ 
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family is feasible170. Increased expression in synovial tissues of 
arthritis patients of dnaJ proteins has been reported by several 
authors and may further contribute to the regulation of immune 
responses169,171. Interestingly, HSP40 (dnaJB1) has been 
reported to be a mechanosensitive gene172 that may be 
extremely relevant in linking immune activation and physical 
stress in the joint. 
HSP60 family 
Similar to the dnaJ family, research on the HSP60 family in the 
arthritis field has primarily focused on studying autoimmune 
responses to self and bacterial HSP60s (reviewed in Vercoulen 
et al.173). It is well known that T cell–recognizing self HSP60 
plays a role in disease protection by inducing a tolerogenic effect 
in arthritis174. However, very little is known about how these 
proteins function in stromal tissues of the joint and how 
changing expression levels in stromal tissues may influence 
immune responses. HSP60 has been reported to regulate 
osteoblast survival175 and bone marrow mesenchymal cell 
apoptosis176. Interestingly, HSP60 induces pro-inflammatory 
cytokine secretion through mitogen-activated protein kinase 
(MAPK) activation in other mesenchymal stem cell (MSC)-
derived cell types, such as adipocytes177. This might be 
important in the context of the elevated levels of HSP60 in the 
synovium174, suggesting a pro-inflammatory role of HSP60 in 
the synovium. 
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Small HSPs 
A particular class within the HSPs are the small HSPs (sHSPs). 
sHSPs are a family of proteins with molecular weights <30 
kDa178. The proteins are structurally characterized by a 
conserved α-crystalline domain that is flanked by non-
conserved sequences essential for chaperone function179. The 
human genome encodes 10 members of the sHSP family. Some 
of these are expressed ubiquitously (such as HSPb1, HSPb5, 
HSPb6 and HSPb8), while others have a more restricted 
expression pattern180. From a structural point of view, the sHSP 
family is particularly interesting as they show several 
phosphorylation sites and tend to form oligomeric structures181. 
The phosphorylation status of sHSPs may alter their subcellular 
localization and function. For example, in osteoblasts the 
unphosphorylated HSPb1 acts as a positive regulator of bone 
calcification, in contrast to phosphorylated HSPb1182. Typically 
sHSPs, similar to other HSPs, primarily function to protect cells 
against stress factors. Unlike the large HSPs, the sHSPs do not 
consume ATP to refold proteins. The expression of sHSPs may 
be induced by various stresses, such as heat shock, oxidative 
stress and chemical stresses. Besides, sHSPs show a 
constitutive expression in particular tissues. In these tissues 
these molecular chaperones are implicated in many different 
cellular processes (reviewed in Haslbeck et al.181). This is 
primarily demonstrated by several congenital diseases that are 
associated with mutations in these proteins. For example, 
mutations in the HSPb1 and HSPb8 genes are associated with 
45 
 
Charcot–Marie–Tooth disease and distal motor 
neuropathy183,184, while mutations in the HSPb5 protein have 
been associated with myopathy126 and cataracts185. 
HSPb1, together with large HSPs, was previously shown to be 
dysregulated in RA synovial tissue186. Our own group previously 
demonstrated that HSPb1 as well as HSPb5 are down-regulated 
in OA chondrocytes and that the expression is regulated by 
proinflammatory cytokines187,188. Moreover, it was clearly shown 
that dysregulation of both HSPb5 and HSPb1 have a major 
impact on the differentiation status as well as the cytokine 
secretion of chondrocytes. Indeed, HSPb1 directly influences the 
IL-1β-induced gene expression in human articular 
chondrocytes189. A similar relationship between HSPb1 and 
TNF-α was recently shown in osteoblasts190. Our observations 
of lowered expression of HSPb1 in OA cartilage and the 
observation that suppressed HSPb1 expression results in a 
decreased responsiveness towards IL-1β may contribute to the 
well-known reduced responsiveness of OA cartilage191 to IL-1β. 
Such a mechanism may represent another way in which HSPs 
regulate cell/tissue defense under stress conditions such as OA. 
Anti-inflammatory properties for HSPb5 were described through 
an extracellular mechanism. Indeed, sHSPs are primarily found 
in the nucleus and cytosol, similar to other chaperones. 
However, it has been described that HSPb5 may be secreted 
from cells via exosomes192, opening new avenues in our 
understanding of sHSPs. Indeed, Rothbard et al.193 recently 
demonstrated that systemic administration of HSPb5 has a 
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therapeutic effect in autoimmune disease [the experimental 
autoimmune encephalomyelitis (EAE) model of multiple 
sclerosis] by binding proinflammatory proteins, in particular 
acute-phase proteins such as complement factors. Given the 
increasing evidence for a role of complement factors in 
degenerative joint diseases97, studying the interactions between 
complement and sHSPs may be an interesting avenue for future 
research, especially given the potential role of sHSP levels in 
joint diseases. Moreover, the authors reported temperature-
dependent binding capacity, which may be extremely relevant 
at sites of inflammation. Apart from protein–protein interactions 
of sHSPs with inflammatory proteins, sHSPs such as HSPb8 and 
HSPb4 may also act as Toll-like receptor ligands194. Here, the 
authors propose HSPb8/TLR4 signaling as a potential 
amplification loop in RA pathogenesis194. In this context, Toll-
like receptor (TLR) signaling is well known to be involved in the 
onset and pathogenesis of experimental arthritis195,196. 
Other HSPs 
Several other proteins act as heat-inducible molecular 
chaperones but are not classified in any particular HSP families. 
For example, RA-related antigen 47 kDa (RA-A47; HSP47) acts 
as a collagen-specific molecular chaperone assisting in the 
maturation of collagens197,198, a process that is crucial for 
normal cartilage development and endochondral bone 
formation199. Indeed, a missense mutation in the gene encoding 
HSP47 is associated with severe osteogenesis imperfecta200. 
HSP47 has been identified as an antigen expressed by human 
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chondrocytes showing immunoreactivity with sera from RA 
patients201. Interestingly, TNF-α and other proinflammatory 
cytokines caused down-regulation of HSP47 expression in 
chondrocytes and an altered subcellular localization (i.e. cell 
surface appearance), which may represent the mechanism for 
the recognition of RA-A47 as an autoantigen during RA202. 
HSP-
family 
member Biological effect  
 
HSP90 
  
HSP90 
(HSPC1 
and 
HSPC3) 
Pleiotropic effects. Targeting HSP90 suppresses 
inflammation [24], reduces expression of matrix 
degrading enzymes [22] but also induces 
osteoclastogenesis [25, 26]. 
 
TRAP1 Promotes chondrocyte survival under hypoxic 
conditions [107]. 
 
gp96 Activates macrophages, suspected to contribute to 
chronicity of  inflammation [28, 29] 
 
HSP70   
HSP70  Extracellular HSP70 suppresses cytokine secretion 
from FLS[42]; involved in tolerance and autoimmune 
processes [33, 37]. 
 
HSP72 Reduces synovial inflammation in animal models [43].  
GRP78 Reduces synovial proliferation [46], increases survival of 
chondrocytes [47] and promotes mineralization [48]. 
 
sHSP   
HSPb1 Involved in cytokine expression in cartilage [71]  
HSPb5 Involved in regulation of cartilage metabolism [72]  
HSPB8 TLR ligand, may amplify inflammation responses [79]  
Other   
HSP47 Involved in cartilage and bone development [84], may act 
as an auto-antigen in RA[86] 
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Clinical applications 
As mentioned earlier, the primary research on HSPs has been 
done on the immunogenic role of HSP fragments and how these 
can modulate the immune system and contribute to 
inflammation. The working mechanism is based on the findings 
that HSPs may act as bystander antigens that can induce 
regulatory immune responses. A lot of pre-clinical work has 
been performed in animal models to induce tolerization, 
including work on GRP78203, HSP60204 and HSP10205. This has 
resulted in a phase II clinical trial with positive results in terms 
of the impact on inflammation170. In another study the 
chaperonin HSP10, a reported inhibitor of TLR signaling, was 
administered and resulted in short-term suppression of 
symptoms in RA205. 
In the cancer field a lot of research effort is put into developing 
HSP inhibitors. These inhibitors block the anti-apoptotic 
function of HSPs in tumor cells, thereby making the tumor more 
sensitive to other anti-cancer agents. Since inflammatory 
synovia are characterized by high levels of HSPs, such an 
approach may be useful to dampen synovial proliferation. 
However, as described earlier, HSPs may have protective effects 
under some conditions, or in some tissues promoting apoptosis 
may not be desirable (e.g. chondrocytes). Moreover, their 
ubiquitous expression and broad interaction profile hamper the 
development of therapeutic strategies that target HSPs. Limiting 
the side effects of such therapies remains a challenging task. 
Further insights into the mechanisms involved in HSP 
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regulation of joint homeostasis are needed to pave the way for 
future therapeutic applications. 
From a diagnostic point of view, altered levels of HSPs186 or 
antibodies to HSPs201,206–211 occur in several inflammatory joint 
diseases. Most of these studies compare RA with healthy 
subjects or non-inflammatory controls or report the presence of 
autoantibodies in other inflammatory joint diseases (AS, SLE, 
SS). Although this is interesting from a scientific point of view, 
it is less relevant in a clinical setting. Real diagnostic tests 
should be able to discriminate between inflammatory 
pathologies and be predictive for future disease activity or 
treatment response. For example, anti-GRP78 (anti-BiP) 
antibodies have been shown to be elevated in RA patients 
compared with other inflammatory diseases, healthy controls 
and non-inflammatory joint diseases163,212. Interestingly, these 
antibodies appear several years before initial symptom 
presentation212. Currently, however, little or no information is 
available on the added value of these biomarkers compared with 
current clinical standards such as RF and anti-CCP tests. Such 
information is key to evaluating the clinical usefulness of these 
biomarkers to diagnose disease. 
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2. Research objective 
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Osteoarthritis (OA) is the most prevalent muscoskeletal disease 
with a large socio-economic burden, as it is a major cause of 
disability. Currently, treatment options are still focussed mainly 
on pain relief by NSAIDs, opioids and corticosteroids. However 
these drugs do not mitigate disease progression. 
Chondroprotective drugs (e.g. hyaluronic acid, chondroitin 
sulphates) can also be used but eventually joint replacement is 
considered the end stage treatment option. The search for 
suitable targets and the development of disease modifying drugs 
has been the holy grail in OA research for many decades now. 
Despite increased understanding in the disease pathogenesis in 
the latest decennia, large parts of the disease mechanism 
remain unknown and no disease modifying drug has been 
developed yet. Overall the aim of this research project is twofold. 
Firstly, we aim to add evidence to the concept of OA as whole 
joint failure. On the other hand, we wish to investigate to what 
extent stress related protein families are differentially regulated 
in OA stromal joint tissue. Furthermore we want to address 
whether these families may provide possibilities for disease 
modifying therapies for OA. 
 
The paradigm of OA as a whole joint organ failure has emerged 
in recent years1. Apart from chondrocyte-populated articular 
cartilage which is a major player in OA mechanism, 
subchondral bone, synovium and meniscus have also been 
recognized as players involved in OA development1–3. The 
acetabular labrum is a meniscus-like fibrocartilagenous 
structure in the hip joint. However, the role of the acetabular 
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labrum in OA is unclear. In chapter 1 we aim to further 
contribute to the whole joint concept by investigating if and how 
the metabolism of fibrochondrocytes from acetabular labrum is 
dysregulated in OA. 
 
The joints, and especially weight bearing joints, are continually 
subjected to several types of stresses (e.g. shear, hydrostatic, 
biomechanical and oxidative stress). These stress events can 
trigger the activation of proinflammatory and catabolic 
signalling pathways, resulting in joint degradation4–10. 
Therefore, we aimed to investigate the potential role of a series 
of poorly studied stress related proteins in OA. We therefore 
focussed on two protein families, the short leucine rich repeat 
proteoglycans (SLRP) (Chapter 3.1) and the small heat shock 
proteins (sHsp) (Chapter 3.2).  
 
The SLRP can function as DAMP and interact with the immune 
system11–14, moreover they are an essential part of the normal 
cartilage ECM15. This makes them potential research targets in 
the context of OA and they have been investigated previously in 
OA cartilage16–18, however no data is available concerning their 
role in supporting fibrocartilagenous structures like the 
acetabular labrum. In light of OA as whole joint organ failure we 
wished to extend the knowledge on SLRP into this tissue and 
address to which extent SLRP are distinctly regulated in 
fibrochondrocytes compared to chondrocytes. Additionally we 
wished to examine the functional implication of SLRP 
dysregulation in OA fibrocartilage. Apart from the SLRP family, 
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we aimed to map the transcriptional profile of degenerated 
acetabular labrum compared to non-damaged tissue.  
 
The sHsp are part of a larger family of heat shock proteins 
(HSP)19,20. Some of the larger HSP have been investigated in 
rheumatic diseases, though they are known mostly for their role 
in the immune system and in the context of inflammatory 
arthritis21–24. Even though sHsp have been implicated in 
numerous degenerative human diseases such as 
neurodegenerative disorders (e.g. Alzheimer’s disease, 
Parkinson’s disease) and cardiovascular disease, the role of 
sHsp in arthritis, and especially OA, remains under 
investigated25–29. Based on initial chondrocyte proteome 
studies30,31 performed by our research group, we aimed to 
further investigate the regulation and potential role of sHsp in 
OA development and progression by performing in vitro assays 
on human articular chondrocytes and in vivo studies in 
experimental OA models. 
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Abstract 
Objective 
Articular cartilage is well studied in osteoarthritis (OA). 
However, the role of supporting structures, such as the 
acetabular labrum, a sealing structure surrounding the hip 
joint, has been investigated much less. We recently showed 
that fibrochondrocytic labrum cells are metabolically active. 
This study was undertaken to investigate hip OA–associated 
changes in human acetabular labrum cells. 
Methods 
Microarray analysis was performed to compare OA labrum 
cells to healthy labrum cells cultured in a 3-dimensional 
alginate bead system. Data were analyzed by cluster analysis 
using gene set enrichment analysis software and by gene list 
analysis using PANTHER gene family tools. Selected 
candidates were validated by quantitative polymerase chain 
reaction analysis on labrum and cartilage samples and by 
immunohistochemistry. The functional impacts of the genes 
identified were investigated by in vitro stimulation experiments 
in labrum cells. 
Results 
Pathway analysis revealed increased cytokine and chemokine 
signaling in OA labrum cells, whereas reduced extracellular 
matrix interactions and transforming growth factor β signaling 
were observed. Several genes were significantly differentially 
expressed in OA compared to healthy labrum. We specifically 
focused on 3 small leucine-rich repeat proteins (SLRPs), 
84 
 
osteomodulin, osteoglycin, and asporin, that appeared to be 
distinctly regulated in OA labrum compared to OA cartilage. 
SLRPs were strongly down-regulated in OA labrum but up-
regulated in OA articular chondrocytes. Moreover, in vitro 
stimulation with osteomodulin increased aggrecan expression 
in OA labrum cells. 
Conclusion 
OA labrum fibrochondrocytes have several features similar to 
OA chondrocytes. However, SLRP expression seems to be 
differentially influenced by degeneration in OA labrum 
compared to cartilage, suggesting a specific role for this 
supporting structure in OA. The functional impact of SLRPs on 
labrum cells makes them interesting targets for further studies 
in hip OA. 
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Osteoarthritis (OA) is characterized by a gradual progression of 
extracellular matrix (ECM) degradation resulting in structural 
and functional failure of synovial joints. In degenerative joint 
diseases, the balance between anabolic and catabolic 
responses of the chondrocyte is disturbed, causing a shift 
toward degeneration of the cartilage ECM ([1]). Although OA 
has traditionally been viewed as an articular cartilage disease, 
the current paradigm is that OA is a whole-joint disease 
involving not only the articular cartilage but also synovium, 
subchondral bone, or menisci ([2]). Whereas most studies to 
date have focused on the articular cartilage in OA, much less 
is known about supporting structures such as menisci and the 
acetabular labrum. 
The biomechanical role of the labrum, a fibrocartilagenous 
structure sealing the hip joint, has been investigated ([3]), but 
we recently demonstrated that labrum cells are metabolically 
active fibrochondrocytes that produce and react to 
proinflammatory stimuli ([4]). Based on the knowledge that 
changes in chondrocyte metabolism drive cartilage 
degeneration, we conducted an exploratory genome-wide gene 
expression study to investigate gene expression changes 
associated with labrum degeneration in hip OA. Our goal was 
to investigate potential gene expression differences and 
analyze their functional importance in hip OA pathology. 
Several pathways were strongly activated during labrum 
degeneration. Of particular interest were members of the small 
leucine-rich repeat protein (SLRP) family that were found to be 
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functionally important for matrix synthesis by labrum 
fibrochondrocytes. 
MATERIALS AND METHODS 
Cell isolation and alginate culture 
Acetabular labrum cells were obtained from control subjects 
without OA ( n=3; with a mean ± SD age of 28.3 ± 9.0 years) 
and OA patients (3 men and 2 women with a mean ± SD age of 
59.6 ± 7.8 years). The Ghent University Hospital Ethics 
Committee approved this study, and informed consent was 
obtained from all patients. Acetabular labrum cells were 
isolated as previously described ([4]). Briefly, labrum samples 
from OA patients were collected within 12 hours after total hip 
replacement surgery. Donor samples were obtained within 12 
hours postmortem. Samples were diced into small fragments, 
and cells were isolated by enzymatic digestion with collagenase 
(Sigma-Aldrich) for 6 hours followed by 2 hours with Pronase E 
(Sigma-Aldrich). Trypan blue exclusion indicated that >90% of 
the cells were viable. Chondrocytes from healthy cartilage 
(n=3) and from degenerated cartilage from 4 men and 2 women 
with OA, with a mean ± SD age of 68.2 ± 11.2 years, were 
isolated as previously described by sequential enzymatic 
digestion (with hyaluronidase, Pronase, and collagenase) ([4]). 
The articular chondrocytes were obtained from the knee, 
because it is extremely hard to obtain hip-derived 
chondrocytes, due to local regulatory issues in our tertiary 
center. Both cell types were immediately cultured in a 3-
dimensional alginate bead system (∼50,000 cells/bead) in 
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Dulbecco's modified Eagle's medium supplemented with 10% 
fetal calf serum, 10 units/ml penicillin, 10 mg/ml 
streptomycin, and 0.002M L-glutamine. Medium was replaced 
twice weekly. After 7 days in culture, a stable metabolism with 
restored ECM production was reached ([4]). After the culture 
period, cells were isolated and stored at −80°C until prepared 
for RNA extraction. 
 
RNA extraction and microarray analysis 
RNA was extracted using TRIzol (Invitrogen) and an RNeasy Mini 
kit (Qiagen), according to the manufacturer's instructions. RNA 
samples were submitted to the Nucleomics Core Facility (VIB). 
All samples fulfilled the preanalytic RNA quality control criteria 
(RNA integrity number >8; A260/A280 ratio >1.8). Samples 
were analyzed using the Affymetrix Human Gene 1.0 ST Array. 
Quality control analysis was performed at the VIB microarray 
facility, by displaying the distribution of the perfect match 
values for each hybridization to detect arrays with higher or 
lower overall intensities and by analyzing the number of present 
calls and average background and scaling factors. All arrays 
fulfilled the quality control criteria. Cluster analysis was 
performed using gene set enrichment analysis (GSEA) software 
version 2.013 (Broad Institute of MIT and Harvard) ([5]). GSEA 
(http://www.broadinstitute.org/gsea) and PANTHER 8.2 ([6]) 
(http://www.pantherdb.org), a gene family database, were used 
for gene list analysis. The data discussed in this publication 
have been deposited in the NCBI GEO database and are 
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accessible through GEO Series accession no. GSE60762 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60
762). 
 
Quantitative polymerase chain reaction (qPCR) 
analysis 
RNA was extracted from additional samples, unrelated to the 
microarray analysis samples (obtained from 4 subjects without 
OA with a mean ± SD age of 31.5 ± 9.7 years and from 3 men 
and 5 women with OA with a mean ± SD age of 63.4 ± 12.8 
years) as described above. Genomic DNA removal and 
complementary DNA (cDNA) synthesis were performed using a 
QuantiTect reverse transcription kit (Qiagen) according to the 
manufacturer's instructions. Quantitative PCR analysis was 
performed using a LightCycler 480 real-time PCR system 
(Roche), and the data were analyzed using the ΔΔCt method. 
Reactions were performed in duplicate. QuantiTect primer assay 
numbers are available upon request from the corresponding 
author. All primer sets were validated in-house for specificity, 
by melting curve analysis and efficiency. 
 
Immunohistologic analysis 
EDTA-decalcified paraffin sections of labrum tissue were used 
for immunostaining. Antigen retrieval was performed using 
protease type XIV, followed by 0.5% Triton permeabilization. 
Sections were blocked for 1 hour with 5% normal goat serum in 
3% bovine serum albumin solution and incubated overnight at 
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4°C with anti-asporin antibody (ab58741), anti-osteomodulin 
antibody (ab154249), or anti-osteoglycin antibody (ab110558) 
(Abcam). Alexa 488–conjugated or Alexa 647–conjugated goat 
anti-rabbit IgG antibody (diluted 1:200; Invitrogen) was 
incubated for 1 hour, and sections were mounted with ProLong 
Gold DAPI (Molecular Probes). Sections were washed 3 times 
between incubation steps. Isotype controls were prepared and 
analyzed as negative controls. Staining was examined with a 
Leica TCS SP5 widefield microscope. 
 
In vitro functional studies 
Labrum samples were obtained from 6 patients with hip OA (2 
men and 4 women with a mean ± SD age of 63.6 ± 6.7 years) 
within 12 hours after total hip replacement surgery. Cells were 
isolated and cultured as described above. After 8 days of 
culture, alginate beads were transferred to 24-well plates (10 
beads/well) in serum-free medium containing ITS+1 (insulin–
transferrin–sodium selenite; Sigma-Aldrich). After 1 day, beads 
were stimulated with recombinant osteomodulin (1 ng/ml or 10 
ng/ml) or vehicle for 24 hours followed by RNA extraction, cDNA 
synthesis, and qPCR analysis, performed as described above. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 21. Gene 
expression data were tested using the nonparametric Mann-
Whitney U test. Stimulation experiments were analyzed by 
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nonparametric Wilcoxon's matched pairs signed rank 
test. P values less than 0.05 were considered significant. 
RESULTS 
Genome-wide expression assay and pathway 
analysis indicate a specific expression pattern 
and signaling in degenerated labrum 
 
The results of a previous study by our group indicated a labrum-
specific cell metabolism compared to menisci and articular 
cartilage ([4]). To investigate gene expression changes 
associated with labrum degeneration, gene expression levels in 
cells isolated from 5 OA patients were compared to those in cells 
from 3 control subjects, using the Affymetrix Human Gene 1.0 
ST Array. Quality control analysis was performed, and all arrays 
fulfilled the quality control criteria. Hierarchical cluster analysis 
performed on these data using GSEA software version 2.013 
indicated 2 clear clusters, namely, the OA samples in one group 
and the healthy samples in a separate group, when considering 
the top 100 gene hits. GSEA pathway analysis showed several 
pathways to be significantly enriched in either healthy or OA 
labrum cells (Table 1). We estimated the relevance of the 
pathways identified by using an enrichment score, which 
reflects the degree of enrichment of a specific pathway, and by 
taking into account the nominal P value (estimating the 
statistical significance with a cutoff of 0.05) as well as the false 
discovery rate. 
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Four pathways were of special interest. Cytokine receptor 
interaction and chemokine signaling were enriched in OA cells. 
In contrast, transforming growth factor β (TGFβ) signaling and 
ECM receptor interaction, interactions between ECM 
components and transmembrane receptors such as integrins 
and proteoglycans, were enriched in healthy cells (Figure 1A). 
The enriched ECM receptor signaling is consistent with known 
changes in ECM, such as ECM degradation in OA samples. 
Interestingly, the genes that contributed most to TGF 
enrichment include thrombospondins, TGFβ3, TGFβ receptor 
type II (TGFβRII), and Smad6, a specific inhibitor of Smad1/5/8 
signaling, which was further confirmed by qPCR (Figure 1B). 
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Figure 1.Distorted transforming growth factor β (TGFβ) pathways in osteoarthritic 
(OA) labrum. A, Enrichment plots determined by gene set enrichment analysis (GSEA) 
software, indicating enrichment of the TGFβ signaling pathway (P < 0.012; false 
discovery rate [FDR] 0.288) (left) and extracellular matrix (ECM) receptor interaction 
pathway (P < 0.001; FDR 0.018) (right) in OA labrum compared to healthy labrum. Lower 
plot visualises signal/noise ratio. The enrichment score reflects the degree of 
overrepresentation, the nominal P value estimates the statistical significance of the 
given enrichment score, and the FDR estimates the probability of a false-positive finding. 
Upper portion of the plot depicts the running ES for the gene set walking down the 
ranked list. The peak value is the ES for the gene set. The middle plot indicates where 
the overrepresented genes appear in the ranked list. The bottom portion indicates the 
signal to noise ratio. Heatmaps were generated by GSEA software and indicate the genes 
that contributed most to the enrichment results. Red indicates high expression; blue 
indicates low expression. KEGG = Kyoto Encyclopedia of Genes and Genomes. B, 
Quantitative polymerase chain reaction analysis of additional labrum samples. Reduced 
expression of core contributors in OA labrum cells was confirmed (P = 0.015 for TGFβ3; 
P = 0.065 for Smad6). Values are the mean relative expression as calculated by the ΔΔCt 
method, normalized to housekeeping genes and compared to the reference sample. Bars 
show the mean ± SEM (n = 6 OA samples and 3 healthy samples). ∗ = P < 0.05. TGFβR2 
= TGFβ receptor type II. C, Reduced expression of multiple small leucine-rich repeat 
proteins in OA labrum compared to healthy labrum, as determined by microarray 
analysis. 
 
Functional reduction in SLRP expression in OA 
labrum 
 
Closer inspection of the array revealed 3 members of the SLRP 
family, osteomodulin, osteoglycin, and asporin, to be severely 
down-regulated in OA compared to healthy labrum. Since some 
SLRPs are known to bind TGFβ and influence its signaling, they 
were further investigated. Osteomodulin, osteoglycin, and 
asporin were confirmed by qPCR assays on additional samples 
to be strongly down-regulated in OA compared to healthy 
labrum-derived fibrochondrocytes. The observed 10–24-fold 
down-regulation was statistically significant for each of them 
(P = 0.016 for osteomodulin, P = 0.011 for osteoglycin, and P = 
0.007 for asporin) (Figure 2A). This reduction was shown to be 
driven by interleukin-1β (IL-1β) (Nakajima M, et al: unpublished 
observations). However, in striking contrast, osteomodulin (P = 
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0.032), osteoglycin (P = 0.016), and asporin (P = 0.063) 
expression levels were up-regulated in OA compared to healthy 
knee-derived chondrocytes (Figure 2A).  
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Figure 2. Dysregulation of small leucine-rich repeat proteins (SLRPs) in 
osteoarthritic (OA) labrum.A, Significant down-regulation of all 3 SLRPs (osteomodulin 
[OMD], osteoglycin [OGN], and asporin [APSN]) in OA labrum-derived fibrochondrocytes 
(n = 8) compared to healthy labrum-derived cells (n = 4) (left) and up-regulation of SLRPs 
in OA knee-derived chondrocytes (n = 5) compared to healthy knee-derived chondrocytes 
(n = 4) (right), as determined by quantitative polymerase chain 
reaction. B, Representative images of immunohistochemical staining for asporin, 
osteoglycin, and osteomodulin. Protein abundance was reduced in OA labrum compared 
to healthy labrum. Original magnification × 40. C, Scoring of stained tissue. Samples 
were scored independently by 3 investigators in a blinded manner, on a scale from 0 to 
4 for immunofluorescent intensity. D, Increased aggrecan expression in labrum cells (n 
= 6) stimulated with osteomodulin (1 ng/ml or 10 ng/ml). In A, C, and D, bars show the 
mean ± SEM. Values are the mean relative expression as calculated by the ΔΔCt method, 
normalized to housekeeping genes and compared to the reference sample. ∗ = P < 0.05; 
∗∗ =P < 0.01. 
 
Furthermore, immunohistochemical staining confirmed that 
the down-regulated expression in OA labrum cells was 
associated with a reduced protein abundance of osteomodulin, 
osteoglycin, and asporin (in 3–4 OA samples and 2 healthy 
control samples) (Figures 2B and C). To investigate the 
functional impact of these SLRPs in labrum, qPCR was used to 
analyze the expression profile of labrum cells obtained from 6 
patients with OA and separately stimulated with osteomodulin 
(1 ng/ml or 10 ng/ml) or vehicle. This analysis indicated a dose-
dependent increase in aggrecan expression (Figure 2D). 
Discussion 
This study compared gene expression patterns in healthy and 
degenerated labrum cells, and the results clearly indicate a 
distinct gene expression pattern in degenerated compared to 
healthy labrum cells. Due to the extensive ECM in which 
chondrocytes are embedded, the number of cells that can be 
isolated is too limited to allow extraction of the high-quality RNA 
necessary for microarray studies. However, the alginate system 
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used to culture the isolated chondrocytes is known to maintain 
a stable chondrocyte phenotype ([7]). A clearly distinct gene 
expression pattern was found. The enrichment in cytokine and 
chemokine signaling indicates the presence of a 
proinflammatory milieu in degenerated OA labrum, which is 
consistent with the proinflammatory environment that has been 
shown to be present in OA cartilage ([8]). Moreover, pathway 
analysis indicated that ECM receptor binding was reduced in 
OA labrum cells, which is also consistent with the available data 
that indicate a disturbed ECM homeostasis in articular cartilage 
during OA ([1, 8]). These results indicate that some of the 
processes that occur in degenerated OA chondrocytes are 
similar to those in OA labrum fibrochondrocytes. 
Similar to articular cartilage, the TGFβ signaling pathway is 
disturbed in degenerated OA labrum cells. The role of TGFβ in 
OA, however, is not straightforward ([9]). Canonical TGFβ 
signaling via Smad2/3 pathways plays a role in ECM synthesis. 
TGFβ has also been shown to be involved in osteophyte 
formation, chondrocyte differentiation, and hypertrophy ([9, 
10]). Traditionally, the Smad1/5/8 pathway has been viewed as 
bone morphogenetic protein–dependent signaling, but recently 
it has been pointed out that TGFβ is able to signal via both the 
Smad2/3 and Smad1/5/8 pathways in chondrocytes ([11]). 
Interestingly, in this study, down-regulated expression of 
Smad6, the specific Smad1/5/8 inhibitor, was observed, and it 
was confirmed in labrum cells. Since Smad6 is a specific 
inhibitor of the Smad1/5/8 pathway and has no inhibitory 
influence on the Smad2/3 pathway induced by TGFβ ([12]), the 
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reduced expression of Smad6 in OA labrum cells points to a 
shift in TGFβ signaling from Smad2/3 in healthy labrum cells 
toward the catabolic, hypertrophic Smad1/5/8 in OA labrum 
cells. Furthermore, apart from the shift in TGFβ signaling, a 
reduced sensitivity of the labrum fibrochondrocyte to canonical 
TGFβ signaling is confirmed by the reduced expression of 
TGFβRII ([10]). It has been observed that in chondrocytes, 
proinflammatory cytokines such as IL-1β can induce this shift 
in TGFβ signaling via reduced TGFβRII expression ([10]). Given 
the proinflammatory environment that labrum cells are exposed 
to during OA, IL-1β signaling may be involved in the TGFβ 
disturbance observed in labrum cells. Other core contributors, 
such as TGFβ3, which is known to stimulate ECM synthesis, 
and thrombospondin 1, which activates latent TGFβ ([13]), were 
down-regulated in OA labrum, further pointing to a reduced 
availability of active anabolic TGFβ ligands. 
The labrum ECM consists mostly of a collagenous component 
(mainly type I collagen) and proteoglycans (mainly aggrecan, but 
also SLRPs). SLRPs are known to interact with collagen fibrils, 
thereby partially protecting them against degradation by steric 
hindrance from collagenases ([14]). Furthermore, some of the 
SLRPs, including osteomodulin, can bind integrins ([15]), and 
most of them interact with growth factors, such as TGFβ ([16]). 
As such, the SLRPs are not only a structural component of the 
ECM but also function in cell membrane interactions, 
modulating signaling pathways. In our experiments, no direct 
involvement of osteomodulin in the regulation of TGFβ signaling 
could be shown (Juchtmans N, et al: unpublished observations); 
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however, osteomodulin seemed to be a downstream regulator of 
altered TGFβ signaling. These findings are consistent with those 
of previous studies indicating induced osteomodulin expression 
by TGFβ signaling in odontoblasts and pulpal fibroblasts ([17]). 
In the current study, osteomodulin, osteoglycin, and asporin, 3 
chromosomally clustered SLRPs ([18]), were shown to be 
strongly reduced in OA labrum cells. In contrast, SLRP 
expression was increased in OA chondrocytes (Figure 2). This 
clearly indicates a distinct SLRP response in degenerated 
labrum fibrochondrocytes compared to cartilage chondrocytes. 
Moreover, the induction of aggrecan expression by in vitro 
stimulation of labrum cells with osteomodulin suggests that the 
observed reduction in SLRP abundance is functionally 
implicated in the observed disturbed synthesis of ECM proteins, 
namely, aggrecan, by OA labrum fibrochondrocytes. This 
indicates a novel, possibly anticatabolic, role for osteomodulin 
in labrum cell ECM homeostasis. 
Taken together, our results indicate that in addition to 
chondrocytes of the connective tissue, fibrochondrocytes of the 
supporting labrum structure are actively involved in 
degenerative OA. Although similarities with OA cartilage, such 
as enrichment of cytokine signaling, were found, some features, 
such as osteomodulin, osteoglycin, and asporin expression, 
were found to be oppositely influenced in labrum compared to 
cartilage, suggesting a specific role for these supporting 
structures in degenerative OA. Additionally, the reduction was 
shown to be of functional importance in labrum, pointing to a 
novel set of regulators implicated in the pathogenesis of hip OA. 
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ABSTRACT 
 
Objectives: To investigate the role of small heat shock proteins 
(sHsp) in cartilage and fibrocartilage from osteoarthritis and to 
assess their in vivo role in joint degradation and remodeling. 
Methods: Human (fibro)chondrocytes were isolated for mRNA 
expression analysis of sHsp in steady state and upon exposure 
to IL-1β. Mice deficient in both HspB2 and HspB5 were 
compared to controls for cartilage degradation and osteophyte 
formation in two different models: collagen antibody induced 
arthritis (CAIA) and destabilization of medial meniscus (DMM). 
Results: We found HspB1, HspB2, HspB5 and HspB6, but not 
Hsp8, to be downregulated in OA chondrocytes and 
fibrochondrocytes, which could be mimicked by exposure to IL-
1β. In the absence of HspB2/HspB5, a remarkable in vivo 
protection against cartilage degradation and joint remodeling 
was observed in CAIA and DMM.  
Conclusion: Our data are consistent with a model whereby 
reduction of a particular pattern of sHsp protects against OA 
development by modulating cartilage and fibrocartilage 
homeostasis. 
 
Keywords: Osteoarthritis, Cartilage degradation, Small heat 
shock proteins 
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Osteoarthritis (OA), is the most prevalent muscoskeletal 
disease,1,2. However, effective disease modifying drugs are 
currently lacking. Heat shock proteins (Hsp), originally 
identified as stress-inducible proteins, have been suggested to 
play a role apart from stress defense.3–5. Little is known on the 
role of these proteins in joint supporting structures such as 
cartilage and fibrocartilage. Initial studies concerning the small 
heat shock proteins (sHsp) and their involvement in cellular 
pathways suggests they might have a role in arthritis and other 
degenerative diseases.6–9 In this study we aimed to investigate 
their role in joint homeostasis in vitro and in vivo. Our data 
highlight a particular pattern of sHsp to be deregulated in OA 
cartilage and fibrocartilage. We also show this downregulation 
protects against further development of OA.  
 
METHODS 
Cell cultures 
Human chondrocytes [(68.2 (11.2) years; n=6)] and 
fibrochondrocytes [(59.6 (7.8) years] were isolated by sequential 
enzymatic digestion, as previously described.8,10 Chondrocytes 
were isolated from undamaged and OA degenerated articular 
cartilage from knee tissue, fibrochondrocytes were obtained 
from OA degenerated labrum (n=5) or healthy tissue (n=4). 
Isolation occurred within 12 hours after joint replacement 
surgery or postmortem. Cells (50 000 cells/bead) were cultured 
in a 3D alginate beads system in Dulbecco’s Modified Eagle’s 
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Medium supplemented with 10% fetal calf serum, 10 U/ml 
penicillin, 10 mg/ml streptomycin and 0.002M L- glutamine. 
The alginate beads system is created by dropping cell 
suspension containing 2% alginate in a 102mM CaCl2 solution. 
The Ghent University Hospital Ethics Committee approved 
these studies. Informed consent was obtained from all patients. 
After culture period, or stimulation experiments, cells were 
isolated and stored at -80°C until prepared for RNA extraction.  
RNA extraction and qPCR 
RNA was extracted using Trizol (Invitrogen) followed by RNeasy 
mini-kit (Qiagen). Genomic DNA removal and cDNA synthesis 
was performed using the Quantitect reverse transcription kit 
(Qiagen) according to manufacturer's instructions. qPCR 
analysis was performed using the LightCycler 480 Real-Time-
PCR system (Roche) and analyzed using the ∆∆Ct method. 
Reactions were performed in duplicate. Primer assay numbers 
or sequences are available upon request from the corresponding 
author. All primersets were validated in house for specificity, by 
melting curve analysis, and efficiency. 
Mice models 
Double knock out mice were obtained thanks to, Prof 
Wawrousek form the National Eye Institute, NIH, Maryland, 
USA.11 For induction of these arthritis models HspB2/HspB5 
wild type and knockout mice were anesthetized with 100µl/mice 
intraperitoneal injection of ketamine (10ng/ml) and xylazine 
(10mg/ml). Destabilization of the medial meniscus (DMM) was 
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performed in 8 week old mice, as previously described12. Briefly, 
the medial menisco tibial ligament was transected, for sham 
surgery the ligament was exposed and touched. Buprenorphine 
(0.05mg/ml; 50µl/mice) was injected intramuscular after 
surgery. Serum samples were obtained at several time points. 
Mice were sacrificed 20 weeks after surgery. Hind paws were 
isolated for histology. Collagen antibody induced arthritis (CAIA) 
was induced as previously described.13 Briefly, mice were IV 
injected with 120µl antibody cocktail under general anesthesia, 
after 3 days 150µl LPS was injected IP. Serum samples were 
collected at several time points. Mice were sacrificed after 18 
days. Paws were isolated for histology. CTX-II elisa (IDS) was 
performed in duplo on serum samples according to 
manufacturer’s instructions. CAIA is typically used as an 
animal model for rheumatoid arthritis. However when the 
duration of the model is extended by allowing a longer recovery 
phase after inflammation, a remodeling component can be 
observed which makes this model more broadly applicable. 
Histology 
Paws and knee joints were fixed in 4% formaldehyde, decalcified 
in 0.5M ethylenediamine tetraacetic acid at 4°. Paraffin sections 
were stained with safranin-O. Paws were evaluated 
independently by three blinded assessors, and scored on three 
parameters, proteoglycan loss, cartilage degradation and new 
bone formation using a semi-quantitative grading system. 
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Statistical Analysis 
Statistical analysis was performed using SPSS 21. Independent 
samples were tested using non-parametric Mann-Whitney U 
test or independent t test. Paired samples were analyzed by non-
parametric Wilcoxon signed ranked test. p-values less than 0.05 
were considered significant. 
RESULTS 
HspB1, HspB2, HspB5, HspB6 though not HspB8 
are dysregulated in osteoarthritic joint cells 
qPCR expression analysis indicates significant lower expression 
of HspB1, HspB2, HspB5 and HspB6 but not HspB8 in OA 
damaged cartilage compared to chondrocytes from undamaged 
cartilage zones in the same patients (Fig 1 upper left) or intact 
cartilage form healthy donors (data not shown). Moreover IL-1β, 
a key proinflammatory cytokine in osteoarthritis, induces a 
significant downregulation of these four sHsp (HspB1, HspB2, 
HspB5 and HspB6), but not HspB8 in chondrocytes (Fig 1, 
bottom left). 
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Figure 1: Downregulation of sHspB1, B2, B5, B6 but not B8 in human OA 
chondrocytes. Bar charts + SEM. *=p<0,05. mRNA levels have been calculated as the 
relative expression compared to three different household genes. A: Upper: comparing 
the expression levels of HspB1, HspB2, HspB5, HspB6 and HspB8 in chondrocytes 
isolated from visually intact zones and damaged zones of the same knee joint from 4-6 
different patients. In all patients expression levels of HspB1 (p=0,039), HspB2 (p=0,043), 
HspB5 (p=0,043),  and HspB6 (p=0,043), were significantly lower in damaged compared 
to intact cartilage samples. HspB8 expression was not altered. Lower: mRNA levels of 
HspB1 (p=0,039), HspB2 (p=0,043), HspB5 (p=0,018), HspB6 (p=0,018), but not 
significantly for HspB8 (p=0,068), were reduced significantly in IL-1β stimulated 
chondrocytes compared to unstimulated chondrocytes. p values were calculated by 
Wilcoxon signed ranked test p values were calculated by Wilcoxon signed ranked test. 
B: Upper: comparing the expression levels of HspB1, HspB2, HspB5, HspB6 and HspB8 
in fibrochondrocytes isolated from acetabular labrum form OA patients (n=7) and 
healthy donors (n=5). Expression levels of HspB1 (p=0.053), HspB2 (p=0.053), 
HspB5(0.053) and HspB6(0.053) were lower in OA compared to healthy samples. No 
difference in expression levels for HspB8 could be observed. p values were calculated by 
Mann Whitney U test. Lower: mRNA levels of HspB1(p=0.031), HspB2 (p=0.031), 
HspB5(p=0.031), and HspB6(p=0.031),  were significantly reduced in IL-1β stimulated 
fibrochondrocytes compared to unstimulated fibrochondrocytes. HspB8 expression 
remained unaltered. p values were calculated by Wilcoxon signed ranked test. 
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Interestingly, qPCR analysis on acetabular labrum 
fibrochondrocytes isolated from healthy and OA patients 
demonstrates the same sHsp expression pattern (HspB1, 
HspB2, HspB5, HspB6 but not HspB8) as well as an IL-1β 
dependent downregulation of these sHsp in fibrochondrocytes 
(Fig 1, right panel)  
Absence of HspB2 and HspB5 protects against 
joint destruction in experimental OA models 
To investigate the potential influence of the observed reduced 
sHsp expression in OA-patients, double knockout mice deficient 
for HspB2 and HspB5 were used as a model for partial sHsp 
reduction, in two animal models. When subjected to the 
inflammatory collagen antibody induced arthritis (CAIA) no 
differences could be observed in clinical arthritis score (Fig 2a) 
between double knockout (HspB2/B5-/-) and wild type 
(HspB2/B5+/+) littermate controls which suggests HspB2 and 
HspB5 have no effect on inflammation in this arthritis model, 
as also indicated by equal serum levels of IL-6 and MMP-3 (data 
not shown). At endpoint no difference in histological 
inflammation was observed. Interestingly, histological analysis 
showed significantly (p= 0.002) less amounts of proteoglycan 
depletion (Fig 2c,d). Moreover, significant reduced serum levels 
of collagen type II fragments (CTX-II) (p=0.008) (Fig 2b) were 
observed in double knockout mice, indicating these mice are 
protected against inflammation induced cartilage damage.  
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Figure 2: HspB2/B5 -/- are protected against CAIA. A: No difference in clinical arthritis 
score (left) was observed in HspB2/HspB5 -/- (n=20) compared to wild type littermate 
controls (n=21). Mice were scored daily, independently by two blinded persons. B: CTX-
II serum levels at endpoint (18 days after arthritis induction) were lower in 
HspB2/HspB5-/- mice versus controls (p=0.008). C: Histological scoring (0= no 
discoloring; 0,5= single site discoloring; 1= clear discoloring at 2 sites; 2= broad 
discoloring at several sites) indicates a reduced degree of proteoglycan depletion 
(p=0.002) in HspB2/HspB5 -/- compared to controls. D: Representative images of 
proteoglycan destruction as observed in Safranin O stained slices of WT (left) and 
HspB2/HspB5-/- (right) mice. Safranin O stained slices were scored blinded by three 
independent researchers. p values were calculated by independent sample t test. 
 
To confirm the role of sHsp in cartilage degradation, double 
knockout mice were subjected to DMM, a non-inflammatory, 
trauma induced OA model. Histologically, both HspB2/B5+/+ 
and HspB2/B5-/- mice develop a severe degree of OA induced 
cartilage degradation at endpoint, whereas no damage could be 
observed in sham operated mice. Interestingly, osteophyte 
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formation, occurring in later stages of the OA pathology, was 
markedly reduced in the absence of  HspB2/B5, as shown by 
histological safranin O staining images (Fig 3a).  
 
Figure 3: Reduced osteophyte formation in the absence of HspB2 and B5. A: 
Representative images of osteophyte bone new formation destruction in DMM model 
using Safranin O stained slices of HspB2/B5+/+ ( left) and HspB2/HspB5-/- (right) mice 
B: Histological scoring indicates a significant reduced number of osteophytes (p=0.048) 
in HspB2/HspB5 double knock out mice (n=7) compared to wild type littermate controls 
(n=6) (left) as well as reduced incidence of bone new formation (right) in HspB2/HspB5 
double knock out mice compared to wild type littermate controls (lower) Safranin O 
stained slices were scored blinded by 3 independent researchers based upon the 
Glasson scoring system. p values were calculated by Mann Whitney U test 
 
Further quantification indicated a significant reduction in the 
number of osteophytes (p= 0.048) (Fig 3b) as well as a reduced 
incidence of new bone formation in HspB2/B5 knockout mice 
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compared to wild type littermate controls (Fig 3c). These 
findings indicate that HspB2/B5-/- mice are protected from 
experimental OA. 
DISCUSSION 
The small heat-shock proteins (sHsp), consist of 10 members 
several of which are ubiquitously expressed.14,15 Even though 
some sHsp have been implicated in human disease, their in vivo 
role in arthritis and joint degradation remained to be 
investigated 3,16–18. Our goal was to unravel their regulation 
during OA and their potential role in joint degradation. We 
found a particular panel of sHsp to be downregulated in OA 
cartilage and fibrocartilage and most importantly that deficiency 
in HSPB2/B5 is associated with a markedly reduced cartilage 
degradation in vivo. This suggest these sHSP are part of a 
negative regulatory mechanism prohibiting damage and 
ultimate joint failure.  
We investigated the expression pattern of the most prominent 
members of the sHsp family (HspB1,HspB2, HspB5, HspB6 and 
HspB8) in (fibro)cartilage.14,15,19 The distinct expression profile 
between HSPb8 and HspB1, HspB2, HspB5 and HspB6, 
suggests that the latter group plays a similar role in the cellular 
metabolism and may share a common transcription factor. 
Bioinformatics as well as in vitro experiments point to C/EBPβ 
as a common promoting transcription factor for these sHsp (see 
supplemental figure 1). In vitro experiments with C/EBPβ 
inhibitor molecule, however, indicated C/EBPβ is not 
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indispensable for their regulation (suppl Fig 1), which suggests 
co-regulatory pathways may exist.  
To investigate a possible role for the reduced sHsp abundance 
in OA, double knockout mice deficient for HspB2 and HspB5 
were used as an in vivo model.11 These mice show a strikingly 
protective phenotype when subjected to arthritis mice models. 
The HspB2/B5-/-mice were markedly protected from cartilage 
degradation in inflammatory arthritis. Moreover in DMM, an 
aggressive, end-stage trauma-induced OA model, a reduced new 
bone formation by osteophytes was apparent in the absence of 
HspB2 and HspB5. A likely explanation for the observed 
reduction in bone remodeling is that cartilage degradation is 
delayed in these double deficient mice, as observed in the CAIA 
model, which would result in a more extensive bone remodeling 
at the end of the DMM model in the wild type mice because of 
the earlier onset of joint destruction. Alternatively, the sHSP 
have no effect on cartilage degradation and proteoglycan 
depletion in DMM but reduces bone new formation by directly 
interfering with osteophyte formation and pathways of bone new 
formation, independently of cartilage damage. Indeed, our group 
showed earlier that BMP-2 expression, which is strongly 
implicated in OA osteophyte formation 20 and terminal 
chondrocyte differentiation, was downregulated in HspB5 
deficient chondrocytes.7 Further experiments studying the 
progress of proteoglycan depletion and cartilage degradation in 
these mice during DMM will be performed to address these 
questions. 
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Altogether our results point to a specific sHsp group (HspB1, 
HspB2, HspB5 and HspB6) that is consistently downregulated 
in the OA cartilage and fibrocartilage. Furthermore, the findings 
suggest this dysregulation is part of a novel protective feedback 
mechanism against cartilage damage and joint failure.  
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Supplementary Data 
METHODS 
Bioinformatics 
For identification of transcription factors a combination of 
different bioinformatics tools were used. TFdiff ENCODE 
(http://bioit2.irc.ugent.be/tfdiff/encode/) takes as input a set 
of putative functionally related genes and identifies the 
transcription factors with the highest regulatory potential for 
this set of genes based on both over-representation and 
association of ENCODE TF ChIP-Seq peak regions linked to 
their target genes. TFdiff ENCODE Single Gene Regulator 
Analysis (http://bioit2.irc.ugent.be/tyrant/) identifies the 
transcription factors having the highest regulatory potential for 
a gene of interest and PhysBinder 
(http://bioit.dmbr.ugent.be/physbinder/) predicts 
transcription factors binding sites based on motif sequence as 
well as biophysical DNA properties and DNA-protein 
interactions21.  
Cell cultures and expression analysis 
Human synovial fibroblasts were isolated by enzymatic 
digestion (dispase 2mg/ml) of synovial tissue in Dulbecco’s 
modified eagle’s medium supplemented with 10% fetal calf 
serum, 10 U/ml penicillin, 10 mg/ml streptomycin. 24 hours 
before RNA isolations cells were stimulated with 0.1 ng/ml IL-
1β or vehicle. For C/EBPβ inhibition experiments synovial 
fibroblasts were treated for 1 hour with p38 inhibitor 
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SB203580 or vehicle, followed by 4 hours stimulation with or 
without 0.1ng/ml IL-1β. Afterwards RNA isolation was 
performed by the RNeasy mini-kit (Qiagen), according to 
manufacturer’s instructions. Genomic DNA removal and cDNA 
synthesis was performed using the Quantitect reverse 
transcription kit (Qiagen) according to manufacturer's 
instructions. qPCR analysis was performed using the 
LightCycler 480 Real-Time-PCR system (Roche) and analyzed 
using the ∆∆Ct method. Reactions were performed in 
duplicate. Primer assays assay numbers or sequences are 
available upon request from the corresponding author. All 
primer sets were validated in house for specificity, by melting 
curve analysis, and efficiency. 
RESULTS 
C/EBPβ as common transcription factor for sHsp 
panel  
In order to provide insights in the potential molecular 
mechanisms involved in the role of sHSPs, common 
transcription factors were screened by TfDiff Encode. The 
analysis was performed against a background of 30 unrelated 
genes and a background of unrelated sHsp family members. 
This TfDiff Encode output was entered in TfDiff Encode Single 
Gene Regulator Analysis to identify which of the common 
transcription factors regulates these sHsp. CCAAT/enhancer-
binding protein beta (C/EBPβ) was predicted to regulate all four 
sHsp, furthermore apart from HspB4 (Cryaa), which as 
expression restricted to the eye lens, none of the other sHsp 
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family members were predicted to be regulated by C/EBPβ. In 
order to get further support for the role of C/EBPβ in the 
regulation of the sHsp, we also used a different method relying 
on a completely different algorithm for the prediction of 
transcription factor binding sites. In contrast to other state-of-
the-art methods, PhysBinder makes use of both direct (the 
sequence) and several indirect readout features of protein-DNA 
complexes (biophysical properties such as bendability or the 
solvent-excluded surface of the DNA). PhysBinder has been 
shown to make predictions with both high specificity and 
sensitivity(21). The PhysBinder algorithm predicted 3, 2, 4 and 
1 C/EBPβ binding places for respectively HspB1, HspB2, 
HspB5, HspB6 (Fig 4a). These results suggests C/EBPβ as a 
common regulatory transcription factor for this specific sHsp 
panel. Additionally, qPCR analysis of unstimulated as well as Il-
1β stimulated chondrocytes revealed a significant positive 
correlation of C/EBPβ expression levels with expression levels 
of HspB1, HspB2, HspB5, HspB6 but not HspB8 in both 
stimulated and unstimulated conditions (Table 1), further 
supporting a role for C/EBPβ as a promoting transcription 
factor for this sHsp panel.  
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Table 1: Pearson correlation coefficients show a positive correlation between C/EBPβ 
and sHsp expression. Statistical significance is indicated in the table. mRNA levels 
have been calculated as the relative expression compared to three different household 
genes 
  HspB1 HspB2 HspB5 HspB6 HspB8 
Unstimulated Correlation 
index 
0.863 0.760 0.889 0.567 -0.139 
 p-value 0.006 0.029 0.003 0.142 0.742 
IL-1β 
stimulated 
Correlation 
index 
0.902 0.956 0.948 0.882 0.434 
 p-value 0.005 0.001 0.001 0.009 0.331 
 
Incubation of human fibroblasts with a p38 inhibitor, which 
also inhibits C/EBPβ ,strongly reduced IL-1β induced IL-6 
expression (Fig 4c) , however no clear effect of C/EBPβ 
inhibition on IL-1β induced downregulation of sHsp expression 
could be observed in IL-1β stimulated fibroblast which received 
inhibitor prior to IL-1β stimulation (Fig 4b), suggesting C/EBPβ 
is not indispensable for the regulation of this sHsp panel. 
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Figure: A: PhysBinder bioinformatic algorithm revealed 3,2,4 and 1 C/EBPβ binding 
place in the promotor region of respectively HspB1, HspB2, HspB5, HspB6. B: no 
effect of C/EBPβ inhibition could be observed on IL-1β induced downregulation of 
HspB1, HspB2, HspB5, HspB6 in synovial fibroblasts.C: Whereas IL-6 induction is 
strongly reduced by C/EBPβ inhibition . 
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4. General discussion and summary 
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OA is an important muscoskeletal disease and even though it is 
known to be a multifactorial disease, crucial events in the 
pathogenesis still remain elusive. Increasing the insight in OA 
pathogenesis and mechanisms driving its progression is crucial 
to find new targeting strategies to develop disease modifying 
drugs. Since the introduction of the concept of OA as a whole 
joint organ failure1, increasing effort has been made to unravel 
the contribution of joint compartments other than cartilage to 
OA degradation and its interactions with cartilage2–4. In this 
research we contribute to the concept of whole joint organ 
failure by providing evidence for a degeneration-specific gene 
expression pattern in OA labrum fibrochondrocytes which is 
similar in some but distinct in many other aspects from OA 
chondrocytes isolated from the articular cartilage. We have 
demonstrated that during OA development, catabolic pathways 
are activated in acetabular labrum. These may contribute to 
degradation of the normal macromolecular structure of the 
fibrocartilage, ultimately leading to loss of normal ‘supporting’ 
function of the labrum and contributing to joint failure5–7. In our 
further research we have thus focussed on both chondrocytes 
and fibrochondrocytes as primary stromal joint cell types.  
Weight bearing joints are subjected to large amounts of different 
types of stress (biomechanical, shear, oxidative etc.). In healthy 
joints however, this does not lead to joint degradation. We 
hypothesize that in an OA joint, stress related protein families 
may be dysregulated and contribute to OA progression. To 
address the role of stress related proteins in osteoarthritis we 
have focussed on two families: the short leucine rich repeat 
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proteoglycans (SLRP) and the small heat shock proteins (sHsp). 
We show both families are distinctly regulated in degenerated 
connective tissue compared to healthy joint tissue. Moreover we 
provide evidence that both families act as novel regulators of 
ECM degradation since both protein families clearly impact joint 
metabolism and remodelling. 
4.1. sHsp downregulation, a rescue 
mechanism for OA joint remodelling 
sHsp are involved not only in cell stress but in several stress 
unrelated cellular events8–10. Larger Hsp have been implicated 
in arthritis but research into sHsp involvement in stromal OA 
phenotype was lacking11–14. Our research indicates a distinct 
group of four sHsp (HspB1, HspB2, HspB5, HspB6 but not 
HspB8) is consistently downregulated in different cell types 
isolated from (fibro)cartilaginous tissue of OA patients. This 
expression profile suggests that these sHsp may be involved in 
OA progression in stromal cells. Indeed, our findings show 
double knock out mice, deficient in both HspB2 and HspB515, 
were markedly protected from cartilage damage during the early 
phases of joint degradation/remodelling as well as from new 
bone formation by osteophytes in an end stage trauma induced 
OA model when compared with littermate controls. These 
findings are particularly interesting, since most reports on sHsp 
in human disease (e.g. neurodegenerative diseases) have 
pointed out protective effects for this protein family16–18. In these 
diseases, boosting the expression levels of sHsp is considered 
as a potential endogenous rescue mechanism to prevent disease 
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progression17. The protective effects for sHsp in 
neurodegenerative disease have mainly been attributed to their 
chaperone activities and prevention of aggregate 
accumulation18–20. Recently, it was shown by Rothbard et al21. 
that HspB5, can be administrated therapeutically in 
experimental autoimmune encephalomyelitis (EAE), a well-
known animal model for multiple sclerosis21. Our results, 
however, indicate a specific downregulation of HspB1, HspB2, 
HspB5 and HspB6 in OA stromal joint cells, which is not 
observed in neurodegenerative tissue cells. Furthermore, in vivo 
results in sHsp deficient mice suggest this downregulation may 
be part of a feedback mechanism attempting to dampen 
progression of OA induced cartilage damage and ultimate joint 
failure. 
Whether this is a chaperone dependent or independent effect 
remains to be investigated. However, since HspB8, a sHsp with 
high chaperone efficacy20,22, is not downregulated in OA joint 
tissue nor in IL-1β stimulated fibro(chondrocytes) it may be 
anticipated that other cellular functions may be responsible for 
the observed phenotype. The unravelling of upstream pathways 
responsible for the downregulation of specifically HspB1, 
HspB2, HspB5 and HspB6 though not HspB8 may further aid 
in understanding which potential mechanisms may be involved 
in the protective downregulation of sHsp. Our initial in silico 
findings point to CCAAT/Enhancer-binding protein (C/EBPβ) 
as a potential transcription factor specifically for these four 
sHsp (HspB1, HspB2, HspB5 and HspB6). However, the pilot 
inhibitor studies we performed indicate C/EBPβ is not 
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indispensable for sHsp regulation, leading to the hypothesis 
that other co-regulatory pathways might be involved. 
The striking protective phenotype in the HspB2/HspB5 double 
knock out mice also provides leads to guide further research 
into the mechanism of the observed rescue mechanism. 
Especially the reduced osteophyte formation in HspB2/HspB5 
double knock out mice in the DMM model merits further 
discussion. Even though osteophyte formation is a hallmark of 
OA, it has also been considered as a rescue mechanism, since 
osteophytes can stabilise the OA-damaged joint. On the other 
hand, it can increase immobility and pain levels, leading to a 
reduced quality of life for OA patients23. It remains to be 
determined whether the observed impaired osteophyte 
formation is simply secondary to the protective effect on 
cartilage or whether, in addition, sHsp have an additional role 
in the formation of osteophytes. Is cartilage degradation 
retarded in sHsp knock out mice during the DMM model thereby 
delaying the need for joint stabilisation and osteophyte 
formation or are the sHsp directly involved in new bone 
formation pathways? 
4.2. SLRP expression contributes to ECM 
synthesis 
SLRPs are part of the very heterogeneous collection of DAMPs 
and are therefore generally considered as stress related 
proteins.  They have been implied in innate immunity through 
activation of TLR and NLR signalling as well as interaction with 
the complement cascade24,25 and are extremely well suited for 
131 
 
protein-protein interactions26. Moreover an OA-like phenotype 
is observed in several SLRP knock out mice27–30 which indicates 
these proteoglycans may be important in ECM homeostasis. We 
therefore aimed to investigate this family in OA-affected joint 
tissue. The role of SLRP in cartilage is well known and some 
SLRP are upregulated in OA chondrocytes compared to healthy 
chondrocytes30–32. We aimed to investigate the role of this 
protein family in fibrocartilage as well. Surprisingly, our 
findings revealed a strong downregulation of three SLRP: 
osteomodulin (OMD), osteoglycin (OGN) and asporin (ASPN) in 
fibrochondrocytes, in contrast to an upregulation in OA 
chondrocytes. Moreover IL-1β was able to strongly induce this 
SLRP downregulation. Our findings point to a distinct SLRP 
regulation in fibrochondrocytes compared to chondrocytes. 
Although fibrocartilage and cartilage are distinct joint 
structures, we observed similar events are ongoing in both 
tissues in OA. Both tissues are characterized during OA by a 
disturbed TGFβ signalling, which shifts towards catabolic 
downstream events, as well as an enriched cytokine and 
chemokine signalling, creating a more pro-inflammatory 
environment. This observation makes the distinct regulation of 
SLRP between OA fibrochondrocytes and chondrocytes of 
particular interest. In order to further investigate the functional 
significance of the distinct SLRP regulation, we performed in 
vitro stimulation of fibrochondrocytes with full length 
recombinant OMD. OMD was able to dose dependently induce 
aggrecan synthesis, which indicated a pro-anabolic effect of 
OMD in fibrochondrocytes, stimulating ECM synthesis through 
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induction of aggrecan production. As such, SLRP may take part 
in a protective mechanism preventing further damage. 
Currently the functional impact of OMD on articular cartilage 
chondrocytes has not been addressed yet, assuming OMD 
would have the same pro-anabolic effects in chondrocytes as 
well, this would suggest the upregulation of SLRP in OA 
cartilage might be yet another OA-induced protective 
mechanism, apart from the above mentioned sHsp 
downregulation. Furthermore we clearly showed the acetabular 
labrum is actively involved in OA as evidenced by increased 
activation of cytokine and ECM degradation pathways. These 
results further contribute to whole joint organ concept and 
provide additional evidence for the contribution of supporting 
joint structures, like the acetabular labrum, to OA development 
and progression. 
 
In conclusion, we provide two mechanisms of endogenous 
protective mechanisms in (fibro)cartilage degradation. Research 
into the upstream regulators and downstream mechanisms in 
the role of both the SLRP and sHsp may provide novel targets 
that can be modulated to boost endogenously existing 
protecting mechanisms that ultimately may aid to dampen OA 
associated joint degradation. 
  
133 
 
References 
1. Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. 
B. Osteoarthritis: a disease of the joint as an organ. Arthritis 
Rheum. 64, 1697–707 (2012). 
2. Scanzello, C. R. & Goldring, S. R. The role of synovitis in 
osteoarthritis pathogenesis. Bone 51, 249–57 (2012). 
3. Benito, M. J., Veale, D. J., FitzGerald, O., van den Berg, W. B. 
& Bresnihan, B. Synovial tissue inflammation in early and late 
osteoarthritis. Ann. Rheum. Dis. 64, 1263–7 (2005). 
4. Yuan, X. L. et al. Bone-cartilage interface crosstalk in 
osteoarthritis: potential pathways and future therapeutic 
strategies. Osteoarthritis Cartilage 22, 1077–89 (2014). 
5. Dhollander, A. A. M. et al. First insights into human 
acetabular labrum cell metabolism. Osteoarthritis Cartilage 
20, 670–7 (2012). 
6. Fukui, K., Kaneuji, A., Fukushima, M. & Matsumoto, T. Early 
MRI and intraoperative findings in rapidly destructive 
osteoarthritis of the hip: A case report. Int. J. Surg. Case Rep. 
8C, 13–7 (2015). 
7. Fukui, K., Kaneuji, A., Fukushima, M. & Matsumoto, T. 
Inversion of the acetabular labrum triggers rapidly destructive 
osteoarthritis of the hip: representative case report and 
proposed etiology. J. Arthroplasty 29, 2468–72 (2014). 
8. Van den IJssel, P., Norman, D. G. & Quinlan, R. A. Molecular 
chaperones: small heat shock proteins in the limelight. Curr. 
Biol. 9, R103–5 (1999). 
9. Mymrikov, E. V, Seit-Nebi, A. S. & Gusev, N. B. Large 
potentials of small heat shock proteins. Physiol. Rev. 91, 
1123–59 (2011). 
10. Haslbeck, M., Franzmann, T., Weinfurtner, D. & Buchner, J. 
Some like it hot: the structure and function of small heat-
shock proteins. Nat. Struct. Mol. Biol. 12, 842–6 (2005). 
11. Rice, J. W. et al. Small molecule inhibitors of Hsp90 potently 
affect inflammatory disease pathways and exhibit activity in 
models of rheumatoid arthritis. Arthritis Rheum. 58, 3765–75 
(2008). 
12. Schett, G. et al. Enhanced expression of heat shock protein 70 
(hsp70) and heat shock factor 1 (HSF1) activation in 
rheumatoid arthritis synovial tissue. Differential regulation of 
hsp70 expression and hsf1 activation in synovial fibroblasts 
by proinflammatory cytokines, s. J. Clin. Invest. 102, 302–11 
(1998). 
134 
 
13. Huang, Q.-Q. et al. Heat shock protein 96 is elevated in 
rheumatoid arthritis and activates macrophages primarily via 
TLR2 signaling. J. Immunol. 182, 4965–73 (2009). 
14. Lambrecht, S., Juchtmans, N. & Elewaut, D. Heat-shock 
proteins in stromal joint tissues: innocent bystanders or 
disease-initiating proteins? Rheumatology (Oxford). 53, 223–32 
(2014). 
15. Brady, J. P. et al. AlphaB-crystallin in lens development and 
muscle integrity: a gene knockout approach. Invest. 
Ophthalmol. Vis. Sci. 42, 2924–34 (2001). 
16. Benndorf, R., Martin, J. L., Kosakovsky Pond, S. L. & 
Wertheim, J. O. Neuropathy- and myopathy-associated 
mutations in human small heat shock proteins: 
Characteristics and evolutionary history of the mutation sites. 
Mutat. Res. Rev. Mutat. Res. (2014). 
doi:10.1016/j.mrrev.2014.02.004 
17. Edwards, H. V, Cameron, R. T. & Baillie, G. S. The emerging 
role of HSP20 as a multifunctional protective agent. Cell. 
Signal. 23, 1447–54 (2011). 
18. Carra, S. et al. Different anti-aggregation and pro-degradative 
functions of the members of the mammalian sHSP family in 
neurological disorders. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 
368, 20110409 (2013). 
19. Treweek, T. M., Meehan, S., Ecroyd, H. & Carver, J. A. Small 
heat-shock proteins: important players in regulating cellular 
proteostasis. Cell. Mol. Life Sci. 72, 429–51 (2015). 
20. Kurnellas, M. P. et al. Chaperone activity of small heat shock 
proteins underlies therapeutic efficacy in experimental 
autoimmune encephalomyelitis. J. Biol. Chem. 287, 36423–34 
(2012). 
21. Rothbard, J. B. et al. Therapeutic effects of systemic 
administration of chaperone αB-crystallin associated with 
binding proinflammatory plasma proteins. J. Biol. Chem. 287, 
9708–21 (2012). 
22. Shemetov, A. Structure, properties, and functions of the 
human small heatâ€•shock protein HSP22 (HspB8, H11, 
E2IG1): A critical review. J. Neurosci. … 269, 264–269 (2008). 
23. Blom, A. B. et al. Synovial lining macrophages mediate 
osteophyte formation during experimental osteoarthritis. 
Osteoarthritis Cartilage 12, 627–35 (2004). 
24. Schaefer, L. et al. The matrix component biglycan is 
proinflammatory and signals through Toll-like receptors 4 and 
2 in macrophages. J. Clin. Invest. 115, 2223–33 (2005). 
135 
 
25. Babelova, A. et al. Biglycan, a danger signal that activates the 
NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. 
Chem. 284, 24035–48 (2009). 
26. Iozzo, R. V. The family of the small leucine-rich proteoglycans: 
key regulators of matrix assembly and cellular growth. Crit. 
Rev. Biochem. Mol. Biol. 32, 141–74 (1997). 
27. Wadhwa, S., Embree, M., Ameye, L. & Young, M. F. Mice 
deficient in biglycan and fibromodulin as a model for 
temporomandibular joint osteoarthritis. Cells. Tissues. Organs 
181, 136–43 (2005). 
28. Nuka, S. et al. Phenotypic characterization of epiphycan-
deficient and epiphycan/biglycan double-deficient mice. 
Osteoarthritis Cartilage 18, 88–96 (2010). 
29. Gill, M. R., Oldberg, A. & Reinholt, F. P. Fibromodulin-null 
murine knee joints display increased incidences of 
osteoarthritis and alterations in tissue biochemistry. 
Osteoarthritis Cartilage 10, 751–7 (2002). 
30. Ni, G.-X., Li, Z. & Zhou, Y.-Z. The role of small leucine-rich 
proteoglycans in osteoarthritis pathogenesis. Osteoarthritis 
Cartilage 22, 896–903 (2014). 
31. Duval, E. et al. Asporin expression is highly regulated in 
human chondrocytes. Mol. Med. 17, 816–23 (2011). 
32. Melrose, J. et al. Fragmentation of decorin, biglycan, lumican 
and keratocan is elevated in degenerate human meniscus, 
knee and hip articular cartilages compared with age-matched 
macroscopically normal and control tissues. Arthritis Res. 
Ther. 10, R79 (2008).  
  
  
136 
 
  
137 
 
5. Samenvatting 
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Osteoartritis is een belangrijke speler op het veld van verlies van 
mobiliteit en levenskwaliteit. In een verouderende maatschappij 
zal osteoartritis een steeds grotere rol gaan spelen. 
Desalniettemin zijn de behandelingsopties nog steeds erg 
beperkt, daar waar voor andere reumatologische aandoeningen 
zoals reumatoïde artritis (RA) en spondylartritis (SpA) de laatste 
decennia grote sprongen voorwaarts gemaakt zijn in 
behandelingsmethoden, zeker met de komst van biologicals die 
ingrijpen op het ziekteverloop zelf. Voor OA blijven we beperkt 
tot pijnbestrijding en chondroprotectieve medicatie zoals 
hyaluronzuur en chondroïtinesulfaat, maar uiteindelijk zal 
orthopedische chirurgie vaak noodzakelijk zijn als laatste 
redmiddel. Het blijft wachten op een eerste effectieve 
behandelingsmethode die het ziekteverloop een halt kan toe 
roepen. Een belangrijke struikelblok hierbij is dan ook een 
gebrek aan inzicht in het ziekteproces van OA. Slechts in de 
laatste twee decennia is er een shift te merken in onderzoek 
naar OA van een visie op OA als zuivere slijtage van kraakbeen 
naar een ziekteproces waarbij het volledige gewricht alsook 
subtiele inflammatie een rol spelen.  
Het was dan ook de doelstelling van deze thesis om bij te dragen 
aan een beter begrip van factoren betrokken in het ontstaan en 
verloop van OA. Er werd hierbij gekozen om te focussen op de 
stromale gewrichtscomponenten. Enerzijds werd de rol van 
kraakbeen-ondersteunende gewrichtsstructuren bestudeerd, 
met name het acetabulair labrum. Anderzijds werden eerste 
stappen gezet in het begrijpen van de rol van twee specifieke 
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proteïnenfamilies in het OA ziekteproces, short leucine rich 
repeat proteins (SLRP) en small heat shock proteins (sHsp). 
In Hoofdstuk I komen we terug op het actabulair labrum en de 
SLRP. Onze studie toont een OA-specifiek expressiepatroon aan 
voor labrum fibrochondrocyten. Hoewel dit expressiepatroon 
zeker sterke gelijkenissen vertoont met het OA fenotype van 
kraakbeen chondrocyten, zoals blijkt uit de verhoogde productie 
van pro-inflammatoire en katabolische cytokinen en de 
verlaagde expressie van matrixcomponenten en TGFβ pathway-
moleculen, zijn er ook belangrijke verschillen. Opvallend 
verschillend was de regulatie van SLRP in OA labrum 
fibrochondrocyten in vergelijking met kraakbeen chondrocytes. 
Daar waar in kraakbeen de expressie van osteomoduline (OMD), 
osteoglycine (OGN) en asporine (ASPN) verhoogd zijn, stelden we 
vast dat in labrum een sterke reductie van deze drie SLRP 
optrad. Mogelijks wordt deze reductie gemedieerd door pro-
inflammatoire cytokines, wat gesuggereerd wordt door een IL-
1β geïnduceerde reductie van expressie in vitro. Gebaseerd op 
de dosisafhankelijke inductie van aggrecan expressie in 
fibrochondrocyten door osteomoduline, suggereren we verder 
dat deze SLRP betrokken kunnen zijn in het behouden van 
matrix homeostase, als anti-katabolische regulatoren. 
Hoofdstuk II verschaft ons een vernieuwend inzicht in de 
expressie en functionele rol van sHsp in OA stromale 
gewrichtsstructuren. Deze resultaten duiden een consistent 
panel van 4 specifieke sHsp aan (HspB1, HspB2, HspB5 en 
HspB6) dat een sterke gereduceerde aanwezigheid kent in OA 
chondrocyten en fibrochondrocyten. De data suggereren dat 
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deze reductie gemedieerd wordt door IL-1β. Hoewel verder 
onderzoek noodzakelijk is om de upstream regulator(en) van 
deze sHsp binnen een OA context te bepalen, wijzen initiële in 
vitro en in silico analyses C/EBPβ aan als mogelijke 
transcriptiefactor voor dit specifieke sHsp panel. Onze in vivo 
experimenten duiden verder aan dat deze reductie een protectief 
effect op kraakbeen homeostase heeft. Muizen deficiënt voor 
zowel HspB2 als HspB5 zijn immers sterk beschermd tegen 
kraakbeendestructie en botnieuwvorming in zowel 
inflammatoire als trauma geïnduceerde artritis modellen. 
Samenvattend kunnen we stellen dat labrum fibrochondrocyten 
functioneel betrokken zijn in OA ziekteverloop en dat hun 
fenotype geen kopie is van het OA chondrocyte fenotype, hoewel 
er ook sterke overeenkomsten zijn. Twee families kleine 
proteïnen werden dieper onderzocht en geven ons een dieper 
inzicht in cellulaire events binnen de stromale 
gewrichtscomponent tijdens OA. Beide groepen zijn betrokken 
in het OA ziekteproces en zouden mogelijks als protectief 
kunnen beschouwd worden. Zeker voor sHsp beschrijven we 
hiervoor sterke in vivo evidentie. Door de verscheidenheid aan 
cellulaire effecten en de alom vertegenwoordiging van deze 
eiwitten is het echter onwaarschijnlijk dat deze proteïnen als 
direct target te gebruiken voor behandelingen. Verder onderzoek 
naar upstream mediatoren zal uitwijzen of indirecte 
targetingstrategieën mogelijk zijn. 
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